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The synthesis and evaluation of structure-activity relationships of saturated nitrogen 
heterocycles is the focal point of various pharmaceutical companies thanks to the high biological 
activity of previously isolated azacycles. Here, we describe an operationally simple and highly 
efficient approach to macrocyclic lactams bearing vicinal stereocenters and a challenging 
cycloalkyne motif. The outcomes are achieved through a novel [4 + 2] cycloaddition reaction 
between an N-iodoarylated-1,3-azadiene and cyclic anhydrides, followed by interception of the 
cycloadducts in cross-coupling manifolds (e.g., Sonogashira coupling) and concomitant lithiation-
cyclization of the tethered alkyne. An unprecedented example of a hydroamino alkylation that is 
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  Regio- and stereoselective functionalization of molecules are two of the most important 
challenges facing the modern synthetic organic chemist. Stereoselectivity is critical to the 
pharmaceutical industry since most drugs are chiral and must be produced in enantiopure or 
diastereopure form for FDA evaluation.1-4 Minor stereoselective and structural modifications 
have been shown to have a major effect on the biological activity of existing pharmaceuticals. 
For example, Adderall and methamphetamine (Figure 1-1) are very similar in structure with the 
only difference being the appendage of a methyl group on nitrogen, which converts the primary 
amine resident in Adderall to the secondary amine present in methamphetamine. 
 
Figure 1-1. Chemical structures of methamphetamine and Adderall. 
 The addition of a methyl group allows for methamphetamine to cross the blood brain 
barrier faster than Adderall, leading to a higher potency.5, 6 While Adderall can be addictive, it is 
used in the treatment of ADHD and narcolepsy due to its stimulating effect.7-18 
Methamphetamine, on the other hand, has no use in treatments and is used solely for the 
euphoric high.5, 6, 19-34 
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  Accordingly, when designing a synthesis, modularity and flexibility need to be taken into 
account. Mechanistic understanding of developing methodology is necessary to advancing the 
field through rational design of substrates and reagents. 
1.1: Diversity-oriented synthesis (DOS) of N-, N,O- N,S-, and N,N- heterocycles 
  Primarily due to the continuous search for new therapeutic agents for current 
difficult-to-cure diseases, the assembly of libraries of nitrogen-containing drug-like cyclic 
molecules with high quality, diversity, and enhanced potency has become a responsibility 
entrusted on synthetic organic chemists. Accordingly, the diversity-oriented synthesis 
(DOS) strategy, which aims to populate new chemical space with drug-like compounds 
that contain a high degree of molecular diversity, has emerged as an essential tool in 
chemical biology and drug discovery programs. However, designing flexible, efficient, 
cost-effective and modular strategies for accessing azaheterocyclic architectures can be 
quite daunting, in part due to conformational constraints and the proneness of some of the 
N-heterocycles to ring-opening. Nevertheless, the biological relevance of N-, N,O- and 
N,S-heterocycles (see chapter 2-1), as well as their architectural complexity, endear them 
to the medicinal and synthesis communities, thus, inspiring the development of 
increasingly more flexible, cutting-edge, time-honored, environmentally benign and cost-
effective strategies for their construction, peripheral functionalization, and evaluation of 
structure-activity relationships (i.e., SAR).35 For example, as shown in Fig. 1-2, some of 
the frequently employed DOS tactics include those developed or popularized by 
aficionados such as Bode36-40 (using SnAP and SLAP reagents), Cossy41, 42 (using a ring 
expansion tactic), Bosch43 (using bicyclic lactams), Charette44 (using pyridinium salts), 
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Comins45, 46/Georg47, 48 (using dihydropyridones), Liebeskind49 (using organometallic 
scaffolding), Beak50, 51/Gawley52-56/O’Brien57, 58/Coldham59, 
60/Meyers61/Clayden62/Beng63-65 (using directed lithiation/ trapping protocols), and 
MacMillan66-69 (using photoredox catalysis). These methods are discussed in detail below. 
 
Figure 1-2. Examples of existing DOS tactics. 
 Access to substituted, N-unprotected heterocycles 4 through tin amine protocol 
(SnAP) reagents 1 reacting with an aldehyde 2 via imine intermediate 3 (Scheme 1-1).70-73 
Many SnAP reagents are commercially available due to the work of the Bode group 
parented with chemical manufactures. Custom SnAP reagents can be prepared using 
simple reagents and can range in functionality. The library of SnAP reagents allows for 
convenient, cost-effective, and modular synthesis of bicyclic and spirocyclic saturated N-
heterocycles with varying ring size.70 Other variations of SnAP reagents have been 
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investigated for their utility in expanding the diversity of N-heterocycle formations (i.e. 


























Scheme 1-1. Access to α-substituted piperazine and other saturated N-heterocycles through 
reaction of SnAP reagent with aldehyde. 
 Biologically active compounds contain various sized heterocycles and the ability to 
expand or contract rings is useful in synthetic applications. The Cossy Group works on the ring 
expansion of leaving-group bearing pyrrolidines 5 to access 2,3,3-trisubstituted piperidines 7 
through an intermediate aziridinium ion 6, which exists as a tight ion pair (Scheme 1-2).77-79 In 
recent years, fluorinated piperidines have been synthesized by opening of the transient 
aziridinium species with fluoride nucleophiles such as diethylaminosulfur trifluoride (DAST).80 
Obvious limitations of the Cossy methodology include the inability to utilize secondary amines 
and N-acyl amines. Additionally, tertiary pyrrolidinols are not tolerated since they instead 


















5 76  
Scheme 1-2. Ring expansion of pyrrolidine derivatives to produce 2, 3, 3-trisubstituted 
piperidines. 
 In Bosch’s synthesis of bicyclic δ-lactams through dynamic kinetic resolution of racemic 
γ-aryl-δ-oxoesters 9 with (R) - or (S)-phenylglycinol 8,81 it was found that cyclodehydration gave 
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trans-3,8-aryl lactams 10-trans as the major diastereomer (Scheme 1-3). Dynamic kinetic 
resolution established that the diastereomeric imines are at equilibrium with four oxazolidines 
with stereogenic centers.82 Through the chair like six-membered lactams, isomeric oxazolidines 
produce the racemic bicyclic lactams. Bosch’s intermediate has been further utilized to access 
functionalized heterocycles and macrocycles.83-85 Through subsequent alkylation of trans-
bicyclic lactams 11, an isomeric 6-disubstituted bicyclic lactam 12 in the approach to (-)-
Quebrachamine 15, an indole alkaloid.86. 
 Another synthetic application of the Bosch synthon is the synthesis of Haliclona alkaloids 
whereby an aza-macrocyclic ring is constructed (Scheme 1-3).87 The reductive opening of δ-
bicyclic lactam 16 followed by hydrogenolysis and protection affords an N-protected 4-methyl-
5-aminopentanol 18, 21. The subsequent synthesis of haliclorensin C uses a nosyl protecting 
group and subsequent alkylation, Dess-Martin oxidation, and Wittig olefination furnish two 
terminal alkene tethers 19. The terminal alkenes then undergo olefin metathesis using Grubbs’ 
second generation catalyst. Further deprotection and reduction afford haliclorensin C 20. 
Haliclorensin synthesis uses a tosyl protecting group that undergoes a series of reactions to 
produce a phthalimido group 22. This group will undergo hydrazinolysis followed by acylation 
to afford two terminal alkene tethers 23. These tethers will be used with a 2nd generation Grubbs 
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 Charette utilizes an N-iminopyridiniums 27 to direct the addition of aryl 28 and alkenyl 
29 Grignard reagents via intermediate bonding of magnesium to the carbonyl of the protecting 




















































Scheme 1-4. Synthesis of N-iminopyridinium and applications to various functionalizations. The 
conditions for reaction 1 and reaction 2 are in the boxes below the compound. 
 Photoredox catalysis harnesses the energy of light to speed up a reaction through single-
electron transfer, which is used to react compounds that are slow or unreactive. David 
MacMillan and co-workers merge photoredox with metal catalysis to achieve α-vinylation and α-
arylation of a cyclic amino acid.94 Photoredox is used due to the α-CH bond being inactivated 
thus allowing photoredox to activate it. Catalytic amounts of photocatalyst and nickel complex 
with ligand were added to an amino acid 31 to produce α-substituted amine 32 as seen in Scheme 
1-5.95 This showcases a new way of sp3-sp2 coupling in the inactivated α position of heterocyclic 
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rings. This new discovery led to easier access to natural products and pharmaceuticals via the 
substituted group. Cyclic enamine 32a is used to form bicycles 33 or natural products 34 and 35 




































Scheme 1-5. Photoredox-metal catalysis of cyclic amino acid to afford α-substituted amine and 
application of cyclic enamine.   
 Direct sp3-sp2 coupling can be applied to assemble a library of compounds including 
heterocycles, thus, providing an effective approach for functionalizing unactivated C-H bonds.  
 Dihydropyridones are doubly saturated pyridones and are used as a synthetic building 
block for various synthetic pathways. The synthesis of dihydropyridone 38 begins with 4-
methoxypyridine 36 reacting with aryl chloroformate followed by Grignard addition and 

















36 37 38  
Scheme 1-6. Synthesis of dihydropyridones through 4-methoxypyridine. R groups are aryl, 
methyl, and alkyl groups. 
 Since the Comins’ synthetic approach to dihydropyridones in the early 1980s, many 
advancements, applications, and adaptations of dihydropyridones have been discovered.97-107 
Attributable to the different functional positions in the dihydropyridones, the synthetic 
applications are expansive and diverse. A few of the possible synthetic transformations can be 







































Figure 1-3. Synthetic transformations of dihydropyridones. Many other transformations can be 
achieved, the ones presented offer a diverse group of reactions. 
10 
 
 The use of amino acids and amino ynone has enabled functionalization in all positions 
and established stereocontrol for the creation of multiple chiral centers. Complete 
functionalization gives a multi-substituted piperidone that can ring open accessing regio- and 
stereoselective alkylamine derivatives with cyanogen bromide.109 Overview of this synthesis is 
































Scheme 1-7. Synthesis of highly functionalized alkylamines through dihydropyridones. Regio- 
and stereoselectivity of the final product is controlled and contained five stereocenters. 
 Organolithium compounds are used in organic synthesis for multiple purposes. 
Conventional lithiation reactions can append a lithium α-amino of an N-protected piperidine, 
however, a racemic mixture is achieved.  Through the use of dynamic thermodynamic resolution 















L* = chiral ligand
 
Scheme 1-8. Catalytic resolution of 2-lithio-N-Boc-piperidine with a chiral ligand. DTR, 
temperature control, and varying concentrations of reagents were used to find the best conditions. 
 Directed lithiation has been utilized in the synthesis of functionalized heterocycles and 
bicycles found in natural products and pharmaceuticals. Due to the proximity of the lithium to 
the heteroatom, fused heterocycles are easily accessible. An example can be seen in Scheme 1-9 
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with the synthesis of a modified harmicine, a tetrahydro-β-carboline, through directed lithiation 

















Scheme 1-9. Synthetic approach to 11-methylharmicine via tetrahydro-2-Boc-pyridindole. Due to 
effects of N-substituents, methyl was the only suitable substituent to undergo further reactions. 
 Other researchers have worked on directed lithiation of heterocyclic motifs and 
advancements are still being made in lithium chemistry.54, 112-123 Uses for lithiation chemistry are 
expansive and diverse due to the reactivity of lithium. 
 
1.2: Relevance of functionalized lactams 
 Lactams are cyclic amides of various ring sizes such as alpha (α), beta (β), gamma (γ), 











-lactam -lactam -lactam -lactam  
Figure 1-4. Various sized lactams. Alpha (3 membered rings), beta (4 membered rings), gamma 
(5 membered rings), and delta (6 membered rings). 
 Lactams differ from acyclic amides due to resonance between the nitrogen atoms lone 
pair and the carbonyl, thus, imposing planarity. Changing the size of ring affects the stability and 
strain of each of the lactams. The β-lactam is one of the most studied heterocycles in the last 
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century due to the impact on antibiotics and other biological activities. Examples of antibiotics 


































Figure 1-5. Examples of biologically active β-lactams.  
 Penicillin was one of the first medications to treat bacterial infections (1928) and still is 
widely used to treat infections, but due to bacteria developing resistance, penicillin is not able to 
treat many bacterial infections. Cephalosporin is a class of antibiotics used in preventive 
medicine and treating various bacterial infections (there are five generations of this antibiotic). 
Aztreonam is a monolactam antibiotic used to treat infections caused by cystic fibrosis and was 
approved by FDA in 1986. In natural product isolation, δ-lactams and γ-lactams have been 
isolated from plants and tend to be highly functionalized. Examples of δ-lactams and γ-lactams 
discovered through natural products are seen in Figure 1-6. The prevalence of highly substituted 
lactams in natural products with biological activation potential has led to an increase in research 
on the synthesis of similar lactams. Functionalizing positions of a lactam can be done by 
hindering attack on the carbonyl side directing C-C bond formation to α or β and the carbonyl of 




Figure 1-6.  Delta-lactams found in natural products. 
 Neophleghenrine A was isolated from Phlegmariurus henyri containing a 9-
azaprotoadamantane core and belong to a family of bioactive alkaloids. Marcfortine B is an 
indolic secondary metabolite with a substituted spirocyclic δ-lactam and γ-lactam. 
Malbrancheamide contains a [2, 2, 2]-diazabicyclic core which is found in diverse biological 
compounds containing the same substituted spirocycle as marcfortine B. Spiradine D was 





1.3: The Castagnoli-Cushman Reaction (CCR): Current state of affairs 
 Reaction of anhydrides with imines has provided access to trans-configured lactams 
through the Castagnoli-Cushman reaction.124 Castagnoli began with simple alicyclic anhydrides 
at elevated temperatures. Later, Cushman expanded the anhydride scope to highly reactive 

































Scheme 1-10. CCR substrate and conditions from 1969 by Castagnoli and expansion by Cushman. 
Alicyclic anhydride (1), homophthalic anhydride (2), and 3-phenylsuccinic anhydride react with 
imine to afford substituted lactamoyl acids. 
 
1.4: Challenges associated with CCR methodology 
 We are aware that the use of 1,3-azadienes with homophthalic anhydride reacts to form 
many adducts. Tamura adducts are the most abundant, which is when the reaction takes place on 
15 
 
the alkene and not the imine. Scheme 1-10 shows the findings from Haimova that homophthalic 









+ >3 other adducts  
Scheme 1-11. Annulation of homophthalic anhydride with 1, 3-azadienes to form Tamura and 
other adducts. 
 Therefore, the alkene is in competition with the imine when undergoing reactions with 
anhydrides. Due to the promiscuous nature of the 1,3-azadienes, they were deemed synthetically 
unattractive as no heterocycle was formed in the process.  
 With knowledge of previous research on common intermediates, we propose our own 









Figure 1-7. Our common intermediate, allylic lactamoyl ester. 
 This intermediate will allow functionalization in every position of an N-heterocycle 
through appending three different functional groups during formation. Synthesis and utility of 





DIVERSITY-ORIENTED SYNTHESIS OF VICINALLY FUNCTIONALIZED 
ALLYLIC LACTAMOYL ESTERS USING THE CASTAGNOLI-CUSHMAN 
REACTION 
2.1: Relevance of N-, N, O- N, S-, and N, N- heterocycles 
 The synthesis and evaluation of structure-activity relationships of saturated nitrogen 
heterocycles are the focal points of various pharmaceutical companies owing to the high 
biological activity of previously isolated azacycles. N-heterocycles are highly prevalent in 
natural products, thus ideal candidates for functionalization through the synthesis of similar 


















manzamine A  
Figure 2-1. Bioactive N-heterocycles. Fittingly, the synthesis and further elaboration of N-
heterocyclic motifs are being explored by many research groups, including but not limited to those 
employed by aficionados such as Bosch, MacMillan, Comins, Gunda, Beak, Gawley, O’Brien, 
Coldham, Beng, Clayden, Cossy and Charette.  
 Lycopladine H was isolated from the club moss Lycopodium complanatum and belongs 
to a family of novel Lycopodium alkaloids. This tetracyclic metabolite exhibits several novel 
architectural features, including an azacyclooctane and a spiro-fused 3-piperidone.127 Due to 
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these features, the synthesis of lycopladine H has proven to be difficult in achieving the 
formation of the complex tetracyclic scaffold. Nakadomarin A is a marine alkaloid of the 
manzamine family containing two bridged N-bicycles. Comprised of an unprecedented 
8/5/5/5/15/6 ring system, nakadomarin A has been isolated from an Okinawan marine sponge 
Amphimedon sp., by Kobayashi and co-workers in 1997.128 Nakadomarin A exhibited a number 
of pharmaceutical applications: a cytotoxicity against murine lymphoma L1210 cells (IC50 1.3 
µg/mL), inhibitor of cyclin-dependent kinase 4 (IC50 9.9 µg/mL), antimicrobial towards 
Trichophyton mentagrophytes (MIC 23 µg/mL), and a Gram-positive bacterium 
(Corynebacterium xerosis, MIC 11 µg/mL).129 Various synthetic methodologies towards 
nakadomarin A have been developed that focus on the synthesis of the core.130-134 However, only 
one total synthesis of (-) has been discovered and two of its antipode.135-137 Manzamine A114, 115, 
117, 118, 120, 138-153 is a marine alkaloid of the manzamine family and was isolated from a sponge in 
the Okinawan sea by Sakai and Higa in 1986. It exhibits a range of biological activities such as 
insecticidal, antibacterial, anti-inflammatory, and anti-cancer and anti-malarial.16 Manzamine A 
contains a pentacyclic core with two Z-olefins, two tertiary amines at ring junctions, five 
stereocenters, and an attached β-carboline heteroaromatic tricyclic system. Similar to 
nakadomarin A, many papers describe the synthesis of the core but only four total syntheses have 
been reported by Winkler154, Martin, Fukuyama155, and Dixon.156 These examples of biological 
active N-heterocycles given evidence that the synthesis of various N-heterocycles can lead to the 
development of new, better pharmaceuticals. 
 N-, N, O- N, S-, and N, N- heterocycles vary from a typical cyclic structure due to the 
effects on chemical properties with the introduction of a heteroatom into the ring system. The 
biological applications and structural complexity of these heterocycles inspire the development 
18 
 
of new synthetic and medicinal application through more efficient strategies of constructing and 
increasing functionality. Piperidines are nitrogen containing six-membered ring systems (N-
heterocycles). They are widely used as a building block and chemical reagent for the synthesis of 
organic compounds with a secondary amine that can be functionalized and effect α,β-positions to 
induce reactivity. Substituted piperidines are widely used in pharmaceuticals due to the 














Figure 2-2. Bioactive piperidines. 
 Paroxetine is a selective serotonin uptake inhibitor for the treatment of depression and 
Parkinson’s disease. Minoxidil is an antihypertensive vasodilator medication for the treatment of 
hair loss. Morpholines are six-membered rings with a nitrogen and an ether oxygen in a 1, 4 
configuration (N, O-heterocycles). The ether oxygen withdraws electron density from the 
nitrogen causing a decrease in nucleophilicity thus the synthesis of morpholines can be 
challenging due to their proneness to ring-opening, stereoselectivity, and economical approaches. 
Substituted morpholines have been isolated from natural products and synthesized with many 
displaying biological activity. Examples of biological active morpholines are represented in 














Figure 2-3. Bioactive morpholines. 
 Pinaverium is an antispasmodic and calcium channel blocker for the treatment of 
functional gastrointestinal disorders. Viloxazine is a selective norepinephrine reuptake inhibitor 
(NRI) used as an antidepressant. Thiomorpholines are six-member rings with a nitrogen and 
sulfur in a 1, 4 configuration (N, S-heterocycles). The properties of these thiomorpholines are 
similar to morpholines with an electron withdrawing effect by the sulfur on the nitrogen. Due to 
the withdrawing effect by the sulfur, the conformation will be pulled by the sulfur away from the 
nitrogen. Sulfur is multivalent but still relatively small in size so it can be useful for increasing 
reactivity. Thiomorpholines can be found in pharmaceutical drugs covering many different 
















Figure 2-4. Thiomorpholines examples of bioactive compounds. 
 DPP-IV inhibitor treats type 2 diabetes (DPP-IV = dipeptidyl peptidase-4). Artemiside is 
used for the treatment of toxoplasmosis, a parasitic infection, which is common among 
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chemotherapy patients. Piperazines are six-membered rings containing two nitrogen atoms in a 1, 
4-configuration (N, N-heterocycles). With the addition of another amine, the basicity of the 
structure will increase due to the lone pair of electrons. Functionalization of the nitrogen can lead 
to double functionalization with the option to place different substituents on each nitrogen. 
Piperazines are found widely in pharmaceuticals but some piperazines are illegal due to 
recreational use because euphoric and stimulant properties. Examples of piperazines in 
















Figure 2-5. Piperazines found in pharmaceutical drugs and illegal drugs. 
 Amoxapine is a tetracyclic antidepressant (part of a large family of antidepressants) used 
in the treatment of major depressive disorders. Trimetazidine is used for the treatment of angina 
(chest pain) and as a cytoprotective anti-ischemic. Benzylpiperazine was synthesized as a 
potential anthelminthic for farm animals but went through clinical trials which determined that 
there was no use for it. However, in the early 1990s, it was found to be used recreationally in 
many parts of the country due to its euphoric and stimuli effects. N-heterocycles are utilized 
heavily in pharmaceuticals due to their biological activities. Synthesis of functionalized N-
heterocycles have proven to be advantageous in discovering new pharmaceuticals thus research 
in this area is in high demand. Development of cost-effective, rapid, and modular synthesis of N-
heterocycles will be discussed in this thesis. 
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 Many of the N-heterocyclic pharmaceutical shown in Figure 2-2, 2-3, 2-4, and 2-5 only 
have N-substituents while leaving most of the ring unsubstituted. Synthetic approaches limit the 
ability to react with the other positions of the ring due to the high reactivity of the heteroatom. In 
the synthesis of these heterocyclic compounds, the heterocyclic portion is not synthesized but 
rather bought due to the complications in synthesizing clean heterocycles. Functionalizing other 
positions of the heterocycles can lead to advancements in pharmaceuticals and applications to 
other isolated compounds. Therefore, redesigning the synthesis of the heterocyclic core could 
lead to the ability to functionalize other positions in the ring. 
2.2: Proposed plan for accessing allylic lactamoyl esters and their potential synthetic 
utility 
As mentioned above, functionalized piperidines, morpholines, thiomorpholines, and 
piperazines constitute the core of several alkaloid natural products, natural or unnatural amino 
acids, ligands and pharmaceuticals.157 
 Circumscribed in these classes of azaheterocycles is a subset, which bears vicinal 
stereocenters. However, controlling the formation of (labile) vicinal stereocenters on the 
skeleton of a piperidine, piperazine or (thio)morpholine poses a considerable challenge, in part 
because sequential substitution of a 2- or 3-substituted cyclic amine derivative is only marginally 
tolerated in most of the existing C-2 or C-3 functionalization strategies. Along these lines, our 
group previously disclosed that the addition of alkyllithium nucleophiles to the β-position of α-
arylated dehydropiperidines followed by interception of the intermediate tertiary organolithium 
with electrophiles furnishes polysubstituted benzylic piperidine derivatives in excellent 
diastereoselectivities (Figure 2-6A).64, 65 Disappointingly, from the standpoint of generality, 
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dehydromorpholines tended to undergo undesirable ring opening. Perhaps more disheartening to 
date is our inability to extend the methodology to α-alkenyl enecarbamates as we are caught at 
the crossroads of alkene vs enecarbamate carbolithiation. 
 Desiring a modular approach to vicinally functionalized and potentially bioactive N-
heterocycles bearing an alkenyl motif at the α-amino position, and seeking to side-step the 
aforementioned limitations, we became interested in investigating the fate of (hetero)cyclic 
anhydrides of type 3 in formal [4 + 2] cycloadditions with 1,3-azadienes such as 4 (Figure 2-6B, 
see 5‒8). We were fully aware of Haimova’s previous findings that while homophthalic 
anhydride (3h) reacts efficiently with simple aromatic imines such as 9 to afford azaheterocyclic 
Castagnoli-type cycloadducts of type 10,126, 158 its reaction with α,β-unsaturated imines such as 4 
proceeds through a plethora of reaction pathways, including Tamura-like159-161 (see carbocyclic 
enaminone 11, Figure 2-6C), Castagnoli-type and Perkin condensation-type125 pathways. Indeed, 
the promiscuous nature of 4 has understandably led researchers to the somewhat hasty 
conclusion that its reaction with cyclic anhydrides is ‘synthetically unattractive’.125 We therefore 
stoically embraced the challenge and surmised that the decreased α-CH acidity of anhydrides 





Figure 2-6. Previous and current work on vicinal functionalized heterocycles. (A) Vicinal 
functionalization of α-arylated dehydropiperidines by carbolithation-trapping64, 65 (B) Proposed 
plan for accessing vicinally functionalized allylic morpholinones, thiomorpholinones and 
piperidinones (C) Annulation of homophthalic anhydride with 1,3-azadienes.126, 158 
 
We reasoned that the appendage of an alkenyl motif on the skeleton of a nitrogen 
heterocycle would pave the way for harnessing several reactivity modes, including 
hydrogenation,162 hydroarylation,163 oxoamination,164 metathesis,165 or trifluoromethylation.166 It 
was, however, recognized that successful implementation of the planned strategy would hinge on 
our ability to (i) achieve substrate-controlled reactivity, (ii) mitigate E/Z isomerization or 
double-bond migration, and (iii) achieve site-selective functionalization of 5‒8. Herein, detailed 
efforts are described. 
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2.3: Results and Discussion 
We initiated studies on the construction of vicinally functionalized allylic lactamoyl 
acids/esters by assembling a diverse range of enolizable cyclic anhydrides and 1,3-azadienes 
(Figure 2-7, see 3a‒h and 4a‒z, respectively). Synthetic procedures for 3 and 4 are detailed in 











2.3.1: Synthesis of allylic morpholinonates 
Foremost among our objectives was to access allylic morpholinonates, which are 
somewhat difficult to synthesize due to the proneness of the morpholine heterocycle to ring 
opening. Gleaning from recent insightful reports (these appeared while this project was at the 
incipient stages) from the laboratories of Burdzhiev167 and Krasavin168 on the use of digylcolic 
anhydride (3b) in a Castagnoli-Cushman reaction with unconjugated imines, model azadiene 4a 
and 3b were engaged in a thermally induced [4 + 2] cycloaddition, using toluene as the solvent. 
Pleasingly, after stirring for 12 h at 90 oC, GC-MS and 1H NMR analyses of the methylated 
crude mixture revealed the presence of a single cycloadduct (Scheme 2-1, see 5a2). The 
exclusive and stereocontrolled formation of the E-configured styrene derivative 5a2 indicates a 
preference for a Castagnoli-Cushman-type reaction over a Tamura-like cycloaddition; the latter 
being the preferred pathway when homophthalic anhydride was employed (Figure 2-6C, see 
11).126 Encouraged by this outcome, and after establishing that toluene out-performs other 
solvents (e.g., EtOAc, 2-MeTHF and 1,4-dioxane), we next moved to evaluate the scope of the 
transformation with respect to the N-substituent and the alkenyl motif. We have found that 
electronically diverse imino dienes are well tolerated. For example, allylic lactam 5c2, which 
bears an electron-donating p-methoxyphenyl (i.e., PMP) group is affordable in impeccable yield 
and in excellent diastereoselectivity. This is a synthetically appealing result given that in addition 
to being readily removable (making it a place-holder for other N-substituents),169 the PMP group 
is amenable to further functionalization under several reaction manifolds, including transition 
metal-catalyzed cross-couplings of the aryl ether subunit. The amenability of electron-poor 1,3-
azadienes of type 4e to this hexannulation protocol has set the stage for rapid installation of 
pharmaceutically relevant motifs such as a trifluoromethylaryl group (see 5d2). N-aryl imino 
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dienes derived from substituted cinnamaldehydes react stereoselectively with diglycolic 
anhydride (see 5e1 & 5f1). Importantly, internally substituted N-aryl-1,3-azadienes seamlessly 
undergo productive hexannulation to afford cycloadducts such as 5g1, without any complications 
arising from E/Z isomerization. This result further highlights the merits of our strategy given that 
stereodefined approaches to trisubstituted styrene derivatives are at a premium.170-173 
Knowing that the nature of the N-substituent present on a morpholine ring can have a 
dramatic effect on its biological activity, the amenability of 1,3-azadienes bearing nonaryl N-
substituents to substrate-controlled hexannulation with 3b, was next explored. Encouragingly, 
cycloalkyl-, allyl-, benzyl-, isopropyl- and tert-butyl-containing imino dienes are all competent 
reactive partners (see 5h2‒r2). 
The relative configuration of the products depicted in Scheme 2-1 was assigned using 
coupling constant analysis (Figure 2-8), and also by analogy to those of the unambiguously 
established benzylic counterparts.168 
2.3.2: Synthesis of thiomorpholinonates from thiodiglycolic anhydride 3c 
 Thiomorpholines have similar properties to morpholines but vary due to the increase in 
size to sulfur from oxygen. The synthesis of thiomorpholine derivatives is even more challenging 
than that of morpholine derivatives due to the enhanced lability hence the increased proneness to 
ring opening. Discovering a selective and effective process for the synthesis of functionalized 
thiomorpholines would be a major advancement. Our studies have revealed that thiodiglycolic 
anhydride (3c), whose α-CH acidity is close to that of homophthalic anhydride (3h) displays 
unproductive reactivity with inherently more reactive N-benzylazadienes, even at 60 oC (Scheme 
2-2, see 6a1/6a1’). The crude mixture in this case showed evidence of formation of the Tamura 




















When tert-butyl-bearing imines are employed, base-mediated methylation of the acid 
leads to incessant ring-opening and instead affords highly functionalized x,b-unsaturated 
acrylates such as 6b2’ and 6c2’. Although this came as a surprise to us since no ring-opening 
occurred when the styrenyl motif was replaced by a phenyl group, we now believe that the 
extended conjugation provides a driving force for the ring opening. Nevertheless, these highly 
functionalized internally substituted dienes represent important intermediates in their own right, 
thus, prompting us to explore the transformation further. In the event, we have found that even 
some aryl-bearing azadienes can afford the versatile dienes (see 6d2’-6f2’). Encouragingly, ring-
opening can be mitigated by performing the methylation under acidic conditions (see 6b2, 6c2, 
and 6j2). 
 
2.3.3: Synthesis of piperidinonates from glutaric anhydrides 
The [4 + 2] cycloaddition strategy described so far is not limited to cyclic anhydrides 
bearing an endocyclic heteroatom such as diglycolic anhydride 3b and thiodiglycolic anhydride 
3c. In work that was mostly done by two undergraduate students in our lab (Hannah Braunstein 
and Monique Khim), but included here for purposes of completeness, we have found that inert 
anhydrides 3a and 3d react satisfactorily with α,β-unsaturated imines, at elevated temperatures, 
to afford the corresponding piperidinonates depicted in Scheme 3 (Scheme 2-3, see 7a−r). The 
amenability of 3e to this hexannulation protocol has set the stage for the installation of α-amido 
quaternary centers. Contrary to 3e, anhydride 3f fails to furnish the desired cycloadducts, even at 
150 oC, presumably due to steric congestion. 
Not all α,β-unsaturated imines that we have evaluated react efficiently and 
stereoselectively with the cyclic anhydrides employed in these studies. For instance, ortho-
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substituted N-aryl-azadienes such as 4w/x barely react with 3a/b. Furthermore, internally 
substituted but sterically encumbered alkenyl imines do not react with glutaric anhydride (see 
7u1). Additionally, the importance of having the styrenyl motif is highlighted by observations 
that azadienes derived from trans-crotonaldehyde fail to furnish the desired allylic lactams (see 
7v1). In these cases, hydrolysis of the azadiene and concomitant nucleophilic attack of the 
anhydride by the ensuing amine are observed. Performing the reaction in the presence of 
molecular sieves fails to negate the hydrolysis. 
 
2.3.4: Synthesis of allylic piperazinonates 
The 2-oxopiperazine motif (see highlighted rings in Fig. 2-9) constitutes the core of 
several alkaloid natural products and pharmaceuticals. It is a privileged substructure whose 
deoxygenated variant (i.e., the piperazine motif) ranks among the top two N-heterocycles in the 
U.S. FDA-approved-pharmaceuticals.157 2-Piperazinones continue to play essential roles as 
conformationally-constrained peptidomimetics given that they mimic inverse γ-turns in peptides, 
which in turn play critical roles in the secondary structures of proteins.174 
Within this research-suitable platform, is a subset of molecules (examples of which are depicted 
in Fig. 2-9) that possesses vicinal stereocenters. However, regio- and stereoselective methods to 
achieve vicinal difunctionalization are relatively rare, in part because sequential substitution of a 
2- or 3-substituted piperazine derivative is either not tolerated or only marginally tolerated in 
most of the existing C-2 and C-3 functionalization strategies.175 Indeed, modular and reliable 
approaches to carbo-monosubstituted piperazines are still at a premium as evident by the fact that 
over 80% of small-molecule piperazine pharmaceuticals contain substitution only at the two 










Fig 2-9   Examples of biologically active 2-oxopiperazines 
 
 Nevertheless, the architectural complexity and biological significance of vicinally 
functionalized 2-oxopiperazine derivatives continue to inspire the synthesis community toward 
developing increasingly more efficient strategies for their construction, peripheral 
functionalization and evaluation of structure-activity relationships (i.e., SAR). Examples of some 
well-heeled strategies for accessing carbo-functionalized piperazines and ketopiperazines include 
those employed by Stoltz176 (using Pd-catalyzed asymmetric allylic alkylation), Kokotos177 
(using organocatalysis), Bode39, 178 (using SnAP reagents), Aggarwal179, 180 (using α-
phenylvinylsulfonium salts), Tiecco181 (using vinyl selenones), MacMillan68, 69 (using 
photoredox catalysis), Schafer182, 183 (using catalytic alkylamination/reduction), Xia184 (using 
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aziridines), Carreira185, 186 (using spirocyclic 3-oxetanones), Wolfe187 (using Pd-catalyzed 
intramolecular carboamination), Mendoza188 (using aluminum organometallics) and Krasavin168, 
189 (using aryl aldimines such and N-tosyl anhydrides). 
 Being cognizant of the biological relevance of functionalized ketopiperazines, and in the 
wake of our recent findings on the morpholine, thiomorpholine, and piperidine heterocycles, we 
next sought to explore the reactivity of N-heterocyclic anhydrides such as 3d1/2 with 1,3-
azadienes, in view of assembling allylic ketopiperazines of type 8. Our choice of 1,3-azadienes 
was mostly guided by observations that common piperazine pharmacophores include N-
alkylpiperazines (e.g., imatinib, a kinase-inhibiting anticancer agent190), N-benzylpiperazines 
(e.g., indinavir, an HIV protease inhibitor191) and N-arylpiperazines (e.g., piribedil, an 
antiparkinsonian agent192). 
As with the other heteroatom-bearing anhydrides, these studies have revealed that 
piperazinonates such as 8a2-8g2 are affordable when commercially available anhydride 3d and 
azadienes of type 4 are refluxed in toluene at 100 oC. (Scheme 2-4). Internally substituted 
styrenes are obtainable is good yield (see 8b2, 8e2, and 8f2). 
 
2.4: Conclusion 
 Modular, cost-efficient, and diastereoselective expansion of the CCR with 1,3-azadienes 
and a library of cyclic anhydride derivatives has been successful in forming a versatile allylic 
lactamoyl ester intermediate. N-aryl and N-alkyl substituted 1,3-azadienes are well tolerated. 
Internal substitution on the styrene moiety is marginally tolerated. The CCR works well when 
diglycolic-, glutaric- and N-heterocyclic- anhydrides are employed. However, as was 










S2: Supporting Information for Chapter 2 
S2-1: General Experimental Information and Procedures  
All experiments involving air and moisture sensitive reagents, such as palladium 
precatalysts and organolithium reagents, were carried out under an inert atmosphere of nitrogen 
and using freshly distilled solvents. Column chromatography was performed on silica gel (230-
400 mesh). Thin-layer chromatography (TLC) was performed using Silicycle SiliaplateTM glass 
backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) and visualized using UV (254 
nm) or CAM, p-anisaldehyde, or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, and DEPT-
135 NMR, COSY 45, HMQC, and NOESY spectra were acquired using DMSO-d6, CD3OD or 
CDCl3 as solvent at room temperature. Chemical shifts are quoted in parts per million (ppm). 
HRMS-EI+ data were obtained using either electronspray ionization (ESI) or electron impact (EI) 
techniques. High-resolution ESI was obtained on an LTQ-FT (ion trap; analyzed using 
Excalibur). High resolution EI was obtained on an Autospec (magnetic sector; analyzed using 
MassLynx). 
 
General Procedure A: Synthesis of 1,3-azadienes 
To a round-bottom flask equipped with a stir bar was added the enal (10 mmol), amine (1 
to 1.5 equiv), benzene (50 mL), and anhydrous MgSO4 (2 g). The cloudy suspension was 
allowed to stir at room temperature. After complete consumption of the amine (based on TLC 
monitoring), the mixture was filtered through and concentrated under reduced pressure to obtain 
the crude enamine, which was used in the next step without further purification. 
Note: The azadienes need to be stored in the refrigerator when not used immediately. 
 
General Procedure B: Reaction of 1,3-azadienes with hexacyclic anhydrides1 
A 5 mL screw-cap vial was flame-dried, evacuated and flushed with nitrogen. A solution 
of the 1,3-azadiene (1.0 mL, 0.10 M in freshly distilled toluene) was added to the vial at room 
temperature followed by the cyclic anhydride (1 to 1.1 equiv). The contents were placed in a pre-
heated oil bath thermostatted at the desired temperature (e.g., 90 oC for diglycolic anhydride). 
After complete consumption of the enal (as judged by TLC and NMR), the mixture/suspension 
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was cooled to room temperature and washed several times with petroleum ether, then 
concentrated under reduced pressure to afford the crude cycloadducts. 
 
 
General Procedure C: Methyl esterification of cycloadducts 
To a stirring suspension of the acid (1 mmol), dissolved in DMF (5 mL), and K2CO3 (6 
equiv) was added methyl iodide (3 equiv) under nitrogen atmosphere. The reaction mixture was 
stirred for 12 to 18 h (TLC monitoring). After complete conversion, it was diluted with water and 
extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, dried 
over Na2SO4 and concentrated in vacuo to give the desired ester. 
 









Prepared from imine 4a (207 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv), using 
General Procedure B. T = 90 oC, time = 18 h. An analytical sample was obtained after a series of 
washes with petroleum ether. 1H NMR (400 MHz, CDCl3) δ 12.86 (1H, s), 7.56 to 7.12 (5H, m), 
6.49 to 6.34 (2H, m), 4.90 (1H, d), 4.58 (2H, dd), 4.20 (1H, d). 13C NMR (101 MHz, CDCl3) δ 
174.7, 167.6, 140.0, 138.3, 137.4, 136.0, 136.0, 134.8, 134.3, 132.7, 131.9, 130.5, 129.8, 129.8, 
129.6, 129.6, 129.4, 129.2, 129.1, 129.0, 128.8, 128.8, 128.4, 127.6, 127.3, 127.2, 125.8, 125.3, 
125.1, 121.0, 75.7, 72.1, 69.8, 68.4, 65.3, 64.9, 63.8. HRMS-EI+ (m/z): calc’d for C19H17NO4 













Prepared from crude 5a1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 280 mg, 83% over 
2 steps, >99:1 dr. 1H NMR (400 MHz, CDCl3) δ 7.48 to 7.19 (10H, m), 6.48 (1H, d), 6.35 (1H, 
dd), 4.85 (1H, d), 4.75 (1H, dd), 4.53 (1H, d), 4.27 (1H, d), 3.77 (3H, s). 13C NMR (101 MHz, 
CDCl3) δ 169.66, 165.73, 139.87, 135.55, 134.57, 129.49, 129.45, 129.26, 129.08, 128.78, 
128.56, 128.35, 127.83, 127.01, 126.78, 124.74, 119.84, 75.79, 65.51, 63.26, 52.07. HRMS-EI+ 











Prepared from imine 4c (221 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv), using 
General Procedure B. T = 90 oC, time = 18 h. An analytical sample was obtained after a series of 
washes with cold petroleum ether. 1H NMR (400 MHz, CDCl3) δ 10.30 (1H, s, broad), 7.40 to 
7.11 (9H, m), 6.47 to 6.32 (2H, m), 4.85 (2H, m), 4.57 (2H, m), 2.30 (3H, s). 13C NMR (101 
MHz, CDCl3) δ 171.2, 167.7, 137.7, 137.3, 135.6, 134.5, 130.5, 129.1, 128.9, 127.2, 127.2, 













Prepared from crude 5b1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 313 mg, 89% over 
2 steps, >99:1 dr. 1H NMR (400 MHz, CDCl3) δ 7.39 to 7.11 (9H, m), 6.45 (1H, d), 6.32 (1H, 
dd), 4.82 to 4.47 (4H, dd), 3.88 (3H, s), 2.38 (3H, s). 13C NMR (101 MHz, CDCl3) δ 169.7, 
165.8, 137.7, 137.2, 135.6, 134.4, 130.1, 128.8, 128.5, 126.8, 126.8, 124.8, 75.8, 65.5, 63.3, 53.0, 










Prepared from imine 4b (237 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv), using 
General Procedure B. T = 90 oC, time = 18 h. An analytical sample was obtained after a series of 
washes with cold petroleum ether. Yield = 300 mg, 84%. 1H NMR (400 MHz, MeOH) δ 7.39 to 
7.12 (5H, m), 6.92 (2H, d), 6.48 (2H, d), 4.79 (1H, d), 4.65 to 4.61 (2H, dd), 4.44 (1H, d), 3.77 
(3H, s). 13C NMR (101 MHz, MeOH) δ 170.9, 167.4, 159.1, 135.9, 134.4, 134.1, 132.5, 128.3, 
128.1, 128.1, 127.9, 127.9, 126.4, 124.8, 114.1, 75.4, 64.6, 63.8, 54.5. HRMS-EI+ (m/z): calc’d 












Prepared from crude 5c1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 338 mg, 92% over 
2 steps, >99:1 dr. 1H NMR (400 MHz, CDCl3) δ 7.38 to 7.25 (5H, m), 7.13 (2H, d), 6.88 (2H, d), 
6.42 to 6.28 (2H, m), 4.77 to 4.44 (3H, m), 3.87 to 3.75 (7H, m). 13C NMR (101 MHz, CDCl3) δ 
169.6, 165.9, 158.8, 136.3, 135.5, 134.6, 132.5, 129.3, 128.8, 128.7, 128.7, 128.5, 128.3, 126.8, 
126.7, 124.7, 114.1, 75.7, 65.5, 63.5, 55.5, 52.7. HRMS-EI+ (m/z): calc’d for C21H21NO5 











Prepared from imine 4e (275 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv), using 
General Procedure B. T = 100 oC, time = 18 h. An analytical sample was obtained after a series 
of washes with cold petroleum ether1H NMR (400 MHz, CDCl3) δ 11.77 (1H, s), 7.69 to 7.24 
(4H, m), 6.43 to 6.30 (2H, m), 4.86 to 4.74 (2H, dd), 4.60 to 4.48 (2H, dd). 13C NMR (101 MHz, 
CDCl3) δ 173.97, 163.48, 139.95, 139.84, 137.52, 137.33, 135.28, 133.90, 132.28, 132.10, 
131.95, 131.67, 131.62, 131.30, 131.11, 130.81, 130.18, 130.10, 129.69, 129.46, 129.28, 129.23, 
129.13, 129.09, 128.82, 128.77, 128.56, 128.32, 128.23, 127.66, 126.94, 126.84, 126.15, 125.72, 
124.97, 124.94, 124.19, 124.15, 124.11, 123.94, 123.42, 122.24, 75.73, 65.02, 63.83. HRMS-












Prepared from crude 5d1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 304 mg, 75% over 
2 steps, >99:1 dr. 1H NMR (400 MHz, CDCl3) δ 7.60 to 7.25 (4H, m), 6.44 (1H, d), 6.28 (1H, 
dd), 4.85 (1H, d), 4.72 (1H, d), 4.56 (1H, d), 4.30 (1H, d), 3.77 (3H, s). 13C NMR (101 MHz, 
CDCl3) δ 170.15, 165.81, 140.32, 136.82, 132.02, 131.69, 131.35, 130.64, 130.06, 129.98, 
129.58, 129.35, 129.17, 128.80, 128.75, 128.72, 128.63, 128.56, 127.99, 126.83, 126.77, 124.94, 
124.62, 124.59, 124.55, 124.51, 124.18, 123.91, 123.87, 123.83, 123.79, 122.85, 122.23, 75.76, 










Prepared from imine 4f (267 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv), using 
General Procedure B. T = 90 oC, time = 18 h. Yield = 314 mg, 82%. 1H NMR (400 MHz, 
CDCl3) δ 11.08 (1H, s, br), 7.51 to 6.77 (8H, m), 6.37 to 6.13 (2H, m), 4.81 to 4.20 (4H, m), 3.76 
to 3.67 (6H, overlapping singlets). 13C NMR (101 MHz, CDCl3) δ 173.9, 167.5, 159.8, 158.9, 
136.2, 134.1, 132.2, 130.0, 129.3, 129.1, 128.7, 128.4, 128.3, 128.3, 128.1, 125.4, 122.2, 122.1, 
114.2, 114.1, 75.9, 68.1, 64.4, 63.8, 55.4, 55.3. HRMS-EI+ (m/z): calc’d for C21H21NO6 












Prepared from imine 4h (305 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 100 oC, time = 22 h. Yield = 295 mg, 70%. 1H NMR (400 MHz, 
MeOH) δ 7.61 to 7.49 (4H, m) 7.32 (2H, d), 6.83 (2H, d), 6.44 to 6.29 (2H, m), 4.87 to 4.23 (4H, 
m), 3.76 (3H, s). 13C NMR (101 MHz, MeOH) δ 170.8, 167.3, 160.0, 140.6, 134.1, 132.5, 131.0, 
130.8, 129.9, 129.6, 129.4, 128.4, 127.7, 124.2, 124.1, 124.0, 123.2, 122.1, 113.7, 75.6, 64.8, 












Prepared from imine 4i (251 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 90 oC, time = 22 h. Yield = 290 mg, 79%. 1H NMR (400 MHz, 
CDCl3) δ 13.10 (1H, s, br), 7.36 to 6.83 (9H, m), 6.49 (1H, s), 4.77 to 4.12 (4H, dd), 3.72 (3H, s), 
1.86 (3H, s). 13C NMR (101 MHz, CDCl3) δ 171.8, 166.3, 159.5, 136.9, 133.8, 131.4, 130.2, 
129.3, 129.2, 128.2, 127.9, 126.1, 114.5, 74.3, 65.3, 55.8, 15.7. HRMS-EI+ (m/z): calc’d for 












Prepared from imine 4k (171 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 12 h. Yield = 217 mg, 72%, 80:20 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.45 to 7.25 (10H, m), 6.69 to 6.56 (2H, dd), 6.26 to 6.14 (2H, dd), 4.51 to 
4.00 (8H, dd), 3.80 to 3.71 (6H, m), 2.65 to 2.60 (2H, m), 0.99 to 0.48 (8H, m). 13C NMR (101 
MHz, CDCl3) δ 170.1, 169.5, 167.8, 167.3, 135.6, 135.6, 133.9, 128.7, 128.7, 128.5, 128.4, 
126.8, 126.7, 125.1, 122.5, 76.3, 75.5, 68.7, 68.1, 60.9, 60.2, 52.7, 52.0, 28.6, 28.3, 8.5, 7.4, 6.3, 












Prepared from imine 4l (185 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 12 h. Yield = 221 mg, 70%, 87:13 dr. 1H NMR 
(400 MHz, CDCl3) 7.54 to 7.14 (5H, m), 6.65 (1H, s), 4.60 to 4.15 (4H, m), 3.79 (3H, s), 2.65 to 
2.49 (1H, m), 1.89 (3H, s), 1.07 to 0.54 (4H, m). 13C NMR (101 MHz, CDCl3) δ 169.9, 168.3, 
136.6, 133.4, 131.6, 130.1, 129.3, 129.0, 128.4, 127.3, 127.2, 126.8, 119.6, 76.8, 74.8, 68.2, 67.6, 
65.7, 65.6, 65.1, 52.8, 52.6, 28.6, 28.4, 15.2, 14.4, 8.5, 8.3, 5.7, 5.0. HRMS-EI+ (m/z): calc’d for 











Prepared from imine 4t (201 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 16 h. Yield = 268 mg, 81%, 85:15 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.47 to 7.22 (4H, major & minor), 6.89 to  6.72 (4H, mixture), 6.56 to 6.47 
(2H, mixture), 6.18 to 5.96 (2H, mixture), 4.47 to 4.09 (8H, mixture), 3.80 to 3.71 (6H, mixture), 
2.60 to 2.47 (2H, mixture), 0.99 to 0.48 (8H, mixture). 13C NMR (101 MHz, CDCl3) δ 170.43, 
169.61, 167.83, 167.38, 159.89, 159.83, 135.05, 133.33, 130.39, 129.71, 128.92, 128.85, 128.31, 
128.09, 127.99, 126.78, 126.47, 122.70, 120.09, 114.5, 114.4, 76.3, 75.6, 68.67, 68.05, 65.35, 
61.02, 55.34, 55.29, 52.64, 52.62, 29.70, 28.55, 8.56, 7.37, 6.33, 5.34. HRMS-EI+ (m/z): calc’d 









Prepared from imine 4v (185 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 16 h. Yield = 277 mg, 88%, 92:8 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.45 to 6.97 (5H,m), 6.48 (1H, s), 5.81 to 5.67 (1H, m), 5.30 to 5.12 (2H, 
m), 4.79, to 4.21 (5H, m), 3.79 (3H, s), 3.30 to 3.22 (1H, dd), 1.84 (3H, s). 13C NMR (101 MHz, 
CDCl3) δ 170.3, 169.7, 168.7, 166.4, 137.5, 136.4, 133.9, 132.9, 132.5, 132.3, 132.0, 131.8, 
130.2, 129.8, 129.1, 129.0, 128.4, 128.2, 128.2, 128.2, 127.4, 127.3, 126.8, 126.6, 119.2, 118.9, 
118.4, 116.6, 77.5, 77.4, 77.2, 76.8, 74.8, 71.3, 69.4, 68.6, 68.1, 67.8, 67.4, 65.3, 63.6, 52.7, 52.2, 
52.0, 50.5, 46.4, 46.3, 41.3, 40.7, 17.2, 14.7, 14.2. HRMS-EI+ (m/z): calc’d for C18H21NO4 











Prepared from imine 4u (221 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 16 h. Yield = 277 mg, 79%, 95:5 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.60 to 6.76 (10 H, m), 6.74 to 6.70 (1H, dd), 6.59 to 6.51 (1H, dd), 5.56 
(1H, d), 4.84 (1H, d), 4.42 to 4.35 (2H, m), 3.77 to 3.66 (2H, m), 3.49 (3H, s). 13C NMR (101 
MHz, CDCl3) δ 170.47, 166.39, 137.01, 136.39, 135.76, 134.93, 131.68, 129.51, 129.37, 129.35, 
129.17, 129.03, 128.98, 128.90, 128.75, 128.21, 127.22, 127.14, 124.77, 75.45, 65.44, 58.58, 









Prepared from imine 4m (227 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 16 h. Yield =282 mg, 79%, 81:19 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.57 to 7.21 (5H, m), 6.73 to  6.51 (1H, dd), 6.33 to 6.14 (1H, dd), 4.64 to 
3.60 (8H, m), 1.93 to 1.36 (12H, m). 13C NMR (101 MHz, CDCl3) δ 193.77, 170.00, 167.60, 
165.07, 164.74, 152.88, 135.73, 134.77, 132.95, 131.34, 129.16, 128.80, 128.75, 128.71, 128.55, 
128.49, 128.41, 128.02, 127.81, 127.29, 126.78, 126.70, 125.10, 124.86, 108.25, 81.25, 77.55, 
77.23, 77.11, 76.91, 76.29, 71.47, 68.71, 68.11, 68.05, 67.80, 65.14, 59.05, 58.40, 57.24, 56.87, 
54.08, 52.69, 52.65, 52.03, 49.94, 44.95, 35.04, 33.41, 33.28, 32.73, 32.63, 32.57, 31.89, 28.06, 
27.71, 27.46, 27.29, 27.27, 26.13, 25.48, 25.34, 25.11, 25.02, 24.07. HRMS-EI+ (m/z): calc’d for 











Prepared from imine 4n (187 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 90 oC, time = 12 h. An analytical sample was obtained after a series of 
washes with cold petroleum ether. 1H NMR (400 MHz, CDCl3) δ 7.43 to 7.22 (5H, m), 6.63 (1H, 
d), 6.30 (1H, dd), 4.95 (1H, d), 4.71 to 4.53 (2H, dd) , 4.21 (1H, d), 1.40 (9H, s). 13C NMR (101 
MHz, CDCl3) δ 173.1, 167.8, 135.6, 133.0, 128.8, 128.8, 128.5, 127.4, 126.8, 126.7, 76.3, 65.6, 









Prepared from crude 5n1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 260 mg, 82% over 
2 steps, 96:4 dr. 1H NMR (400 MHz, CDCl3) δ 7.55 to 7.16 (5H, m), 6.66, (1H, d), 6.26 to 6.09 
(1H, dd), 4.83 (1H, d), 4.58 to 4.32 (2H, dd), 4.25 (1H, d), 3.74 (3H, s), 1.43 (9H, s). 13C NMR 
(101 MHz, CDCl3) δ 170.4, 167.8, 135.7, 135.7, 134.5, 134.0, 132.7, 131.3, 129.1, 128.9, 128.8, 
128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 127.7, 127.2, 127.1, 126.7, 126.6, 125.7, 
80.2, 78.4, 77.6, 77.6, 77.3, 77.0, 76.6, 71.8, 71.7, 70.4, 68.6, 68.1, 68.0, 65.7, 59.2, 58.4, 57.3, 
56.6, 52.6, 52.0, 51.8, 51.0, 45.8, 45.3, 36.5, 29.9, 28.8, 28.4, 28.1, 27.9. HRMS-EI+ (m/z): 














Prepared from imine 4o (201 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 90 oC, time = 18 h. An analytical sample was obtained after a series of 
washes with cold petroleum ether. 1H NMR (400 MHz, DMSO) δ 13.45 (1H, s, br), 7.37 to 7.22 
(5H, m), 6.37 (1H, s), 4.67 to 4.54 (2H, dd), 4.28 to 4.09 (2H, dd), 1.91 (3H, s), 1.37 (9H, s). 13C 
NMR (101 MHz, DMSO) δ 172.2, 166.8, 137.2, 136.9, 129.2, 128.8, 127.3, 127.0, 74.0, 65.4, 
61.4, 58.2, 40.6, 40.4, 40.2, 40.0, 39.8, 39.6, 39.4, 27.9, 16.2. HRMS-EI+ (m/z): calc’d for 










Prepared from crude 5o1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 252 mg, 76% over 
2 steps, >99:1 dr. 1H NMR (400 MHz, CDCl3) δ 7.36 to 7.20 (5H, m), 6.48 (1H, s), 4.62 to 4.53 
(3H, m), 4.23 (1H, d), 3.73 (3H, s), 1.97 (3H, s), 1.46 (9H, s). 13C NMR (101 MHz, CDCl3) δ 
170.9, 167.0, 136.8, 135.3, 129.0, 128.3, 127.1, 77.5, 77.1, 76.8, 74.8, 65.8, 61.6, 60.4, 58.8, 


















Prepared from imine 4r (217 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 90 oC, time = 18 h. An analytical sample was obtained after a series of 
washes with cold petroleum ether. 1H NMR (400 MHz, DMSO) δ 13.38 (1H, s, br), 7.41 (2H, 
d), 6.90 (2H, d), 6.50 (1H, d), 6.30 (1H, dd), 4.74 (1H, d), 4.55 (1H, d), 4.29 to 4.09 (2H, dd), 
3.80 (3H, s), 1.36 (9H, s). 13C NMR (101 MHz, DMSO) δ 172.0, 166.7, 159.6, 133.0, 131.2, 
129.1, 128.3, 127.2, 114.6, 76.2, 68.8, 65.4, 58.5, 57.7, 56.7, 55.7, 40.7, 40.4, 40.2, 40.0, 39.8, 











Prepared from crude 5p1 using General Procedure C. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 274 mg, 79% over 
2 steps, 93:7 dr. 1H NMR (400 MHz, CDCl3) δ 7.48 (2H, d), 6.88 (2H, d), 6.52 (1H, d), 6.09 
(1H, dd), 4.78 (1H, d), 4.55 to 4.34 (2H, dd), 4.19 to 4.15 (1H, dd), 3.79 to 3.71 (6H, overlapping 
singlets),1.33 (9H, s). 13C NMR (101 MHz, CDCl3) δ 170.5, 166.7, 62.5, 159.8, 152.3, 133.9, 
132.1, 130.4, 129.9, 128.4, 128.0, 127.9, 125.4, 123.3, 114.6, 114.2, 114.1, 113.5, 78.6, 77.0, 
76.7, 71.8, 68.6, 68.1, 68.0, 65.7, 59.2, 58.3, 57.4, 56.6, 55.3, 52.6, 51.8, 28.8, 28.4. HRMS-EI+ 













Prepared from imine 4p (305 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedure B. T = 90 oC, time = 16 h. Yield = 295 mg, 82%, 83:17 dr. 1H NMR (400 
MHz, CDCl3) δ 11.31 (1H, s, br), 7.40 to 7.11 (5H, m), 6.62 (1H, d),6.27 to 6.20 (1H, dd), 4.67 
to 4.46 (3H, m), 4.39 to 4.21 (1H, m),4.10 (1H, d), 1.27 to 1.18 (6H, dd). 13C NMR (101 MHz, 
CDCl3) δ 173.6, 172.2, 170.7, 167.4, 167.0, 135.6, 135.6, 133.3, 129.2, 128.8, 128.7, 128.5, 
128.1, 127.2, 126.9, 126.7, 123.8, 77.6, 77.3, 77.0, 76.4, 75.6, 70.8, 68.8, 68.2, 68.1, 68.1, 67.3, 
64.5, 57.0, 55.5, 52.2, 49.0, 47.3, 45.3, 22.4, 20.6, 20.2, 19.6, 19.5. HRMS-EI+ (m/z): calc’d for 











Prepared from imine 4q (187 mg, 1.0 mmol) and diglycolic anhydride (128 mg, 1.1 equiv) using 
General Procedures B and C. T = 90 oC, time = 12 h. Yield =289 mg, 91%, 92:8 dr. 1H NMR 
(400 MHz, CDCl3) δ 7.36 to 7.20 (5H, m), 6.48 (1H, s), 4.62 to 4.53 (3H, m), 4.23 (1H, d), 3.73 
(3H, s), 1.97 (3H, s), 1.46 (6H, dd). 13C NMR (101 MHz, CDCl3) δ 170.3, 166.1, 136.7, 135.6, 
131.2, 129.7, 128.9, 128.7, 128.5, 128.3, 127.3, 127.2, 127.1, 77.7, 77.6, 77.3, 77.0, 76.7, 74.8, 
68.0, 67.3, 64.9, 64.6, 61.8, 60.1, 52.6, 52.4, 51.9, 51.9, 48.0, 46.4, 46.0, 20.2, 30.0, 19.6, 19.3, 
19.0, 18.9, 15.5, 14.6. HRMS-EI+ (m/z): calc’d for C18H23NO4 317.1627; found 317.1622. 
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Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 216.5 mg, 65%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.77 (d, J = 
11.0 Hz, 1H), 7.53 – 7.39 (m, 2H), 7.33 (q, J = 8.5, 7.8 Hz, 3H), 7.24 – 7.17 (m, 1H), 7.02 (d, J = 
15.6 Hz, 1H), 6.66 (s, 1H), 3.70 (s, 3H), 3.37 (s, 2H), 1.30 (d, J = 26.4 Hz, 9H). 13C NMR (101 
MHz, CDCl3) δ 167.3, 166.1, 148.0, 143.3, 135.8, 129.8, 129.5, 129.0, 128.8, 127.9, 127.7, 
127.5, 124.5, 52.8, 52.6, 51.4, 39.2, 28.6, 28.5, 28.4. HRMS-EI+ (m/z): calc’d for C18H23NO3S 










Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 225.4 mg, 62%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 
11.1 Hz, 1H), 7.44 (d, J = 8.3 Hz, 2H), 7.32 (dd, J = 15.5, 11.0 Hz, 1H), 6.97 (d, J = 15.4 Hz, 
1H), 6.87 (d, J = 8.3 Hz, 2H), 6.72 (s, 1H), 3.80 (s, 6H), 3.72 (d, J = 16.0 Hz, 2H), 3.36 (s, 2H), 
3.19 (s, 1H), 1.30 (d, J = 26.3 Hz, 9H). 
13
C NMR (101 MHz, CDCl
3
) δ 167.4, 166.3, 161.1, 
148.8, 143.4, 129.4, 129.0, 128.7, 122.4, 114.4, 55.4, 52.8, 51.5, 51.4, 39.4, 28.6, 28.5. HRMS-












Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 278.9 mg, 79%. 
1
H NMR (400 MHz, Chloroform-d) δ 9.40 (s, 1H), 
7.82 (d, J = 11.1 Hz, 1H), 7.64 – 7.45 (m, 4H), 7.45 – 7.15 (m, 5H), 7.13 – 6.98 (m, 2H), 3.81 (s, 
3H), 3.69 (d, J = 21.0 Hz, 1H), 3.59 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 166.9, 166.8, 149.2, 
144.1, 138.1, 137.9, 135.8, 129.9, 129.5, 129.3, 129.0, 127.9, 127.7, 127.6, 124.3, 124.1, 120.1, 










Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 345.3 mg, 82%. 
1
H NMR (400 MHz, Chloroform-d) δ 9.80 (s, 1H), 
7.96 (s, 1H), 7.82 (dd, J = 13.2, 9.4 Hz, 2H), 7.56 – 7.44 (m, 3H), 7.31 (q, J = 8.8 Hz, 6H), 7.02 
(d, J = 15.7 Hz, 1H), 3.82 (s, 3H), 3.60 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 168.4, 167.5, 
149.6, 144.4, 130.7, 130.3, 130.0, 129.8, 129.5, 129.0, 128.6, 127.8, 127.6, 124.3, 123.9, 123.4, 
122.9, 120.7, 116.4, 116.3, 53.1, 52.7, 40.1. HRMS-EI+ (m/z): calc’d for C21H18F3NO3S 












Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 383.2 mg, 80%. 
1
H NMR (400 MHz, Chloroform-d) δ 9.51 (s, 1H), 
7.92 (s, 1H), 7.62 (dd, 4H), 7.56 – 7.42 (m, 5H), 7.04 (d, 1H), 3.84 (s, 3H), 3.55 (s, 2H). 13C 
NMR (101 MHz, CDCl3) δ 167.2, 149.8, 144.2, 137.8, 135.9, 130.2, 129.2, 129.0, 128.9, 127.7, 
127.6, 124.1, 123.9, 121.8, 87.8, 53.6, 40.3. HRMS-EI+ (m/z): calc’d for C20H18INO3S 









Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 166.7 mg, 50%.
 1
H NMR (400 MHz, Chloroform-d) δ 7.27 (td, J = 
22.3, 20.1, 11.9 Hz, 5H), 6.52 (d, J = 16.1 Hz, 1H), 6.22 (dd, J = 16.0, 4.2 Hz, 1H), 5.28 (s, 1H), 
3.92 (d, J = 2.9 Hz, H), 3.73 (s, 3H), 3.39 (d, J = 15.1 Hz, 1H), 3.17 (dd, J = 14.8, 10.3 Hz, 1H), 
1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.0, 166.7, 135.9, 135.8, 132.7, 131.3, 128.7, 
128.6, 128.3, 128.2, 128.0, 126.7, 126.6, 59.2, 58.3, 58.2, 53.1, 50.0, 47.3, 47.2, 30.0, 29.9, 28.9, 












Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 207.2 mg, 57%. 1H NMR (400 MHz, Chloroform-d) δ 7.28 (m, 
2H), 6.91 – 6.69 (m, 2H), 6.46 (d, J = 16.0 Hz, 1H), 6.07 (dd, J = 15.9, 4.4 Hz, 1H), 5.25 (d, J = 
4.7 Hz, 1H), 3.90 (d, J = 2.9 Hz, 1H), 3.84 – 3.53 (m, 6H), 3.39 (t, J = 15.7 Hz, 1H), 3.15 (d, J = 
14.8 Hz, 1H), 1.45 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 171.1, 166.8, 160.0, 131.0, 130.9, 
130.7, 128.7, 128.4, 127.6, 114.2, 114.1, 59.2, 58.4, 58.2, 55.4, 55.3, 55.2, 53.0, 47.7, 47.5, 31.2, 
28.9, 28.6, 28.4.
 










Prepared from imine 4b (237 mg, 1.0 mmol) and thiodiglycolic anhydride (132 mg, 1.0 equiv), 
using General Procedure B. T = 60 oC, time = 12 h. An analytical sample was obtained after a 
series of washes with cold petroleum ether. Yield = 258 mg, 70%. 1H NMR (400 MHz, CDCl3) δ 
10.96 (1H, br. S), 7.52 to 7.09 (7H, m), 6.91 to 6.79 (2H, d), 6.58 to 6.32 (2H, m), 4.85 to 4.83 
(1H, dd), 3.80 to 3.32 (6H, m). 13C NMR (101 MHz, CDCl3) δ 173.19, 168.27, 158.78, 135.84, 
134.61, 134.11, 130.75, 129.26, 128.06, 126.88, 122.31, 118.93, 66.58, 55.96, 44.84, 28.34. 













Prepared from imine 4i (251 mg, 1.0 mmol) and thiodiglycolic anhydride (132 mg, 1.0 equiv) 
using General Procedure B. T = 60 oC, time = 12 h. Yield = 280 mg, 73%.  1H NMR (400 MHz, 
CDCl3) δ 11.02 (1H, s br), 7.55 to 7.08 (5H, m), 6.95 to  6.81 (2H, d), 6.41 (1H, s), 4.89 (1H, d), 
3.85 to 3.30 (6H, m), 1.86 (3H, s). 13C NMR (101 MHz, CDCl3) δ 172.48, 167.36, 158.59, 
136.78, 135.18, 133.62, 130.15, 129.38, 129.02, 128.75, 127.09, 118.12, 71.05, 55.45, 43.98, 










Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedure B. T = 60 
oC, time = 16 h. Yield = 363 mg, 78%. 1H NMR (400 MHz, CDCl3) δ 11.05 (1H, s br), 7.66 to 
7.57 (2H, d), 7.38 to 7.19 (5H, m), 6.95 (2H, d), 6.46 to 6.39 (2H, m), 4.86 to 4.81 (1H, dd), 3.73 
to 3.36 (3H, m). 13C NMR (101 MHz, CDCl3) δ 174.84, 168.17, 141.39, 138.6, 137.99, 136.24, 
134.74, 129.78, 128.78, 126.90, 125.35, 93.71, 66.28, 44.34, 28.27. HRMS-EI+ (m/z): calc’d for 













Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedure B. T = 60 
oC, time = 22 h. Yield = 407 mg, 85%. 1H NMR (400 MHz, CDCl3) δ 11.04 (1H, s br), 7.81 to 
7.03 (9H, m),  6.59 (1H, s), 4.88 (1H, d), 3.83 to  3.36 (3H, m), 1.87 (3H, s). 13C NMR (101 
MHz, CDCl3) δ 174.93, 167.29, 141.96, 139.91, 138.46, 132.90, 130.73, 129.19, 128.45, 128.03, 












Prepared from thiodiglycolic anhydride (132 mg, 1.0 equiv) using General Procedures B & C. T 
= 60 oC, time = 22 h. Yield = 387 mg, 89%. 1H NMR (400 MHz, CDCl3) δ 7.61 to 7.18 (9H, m), 
6.62 (1H, s), 4.93 (1H, d), 3.93 to 3.87 (4H, m), 3.57 to 3.39 (2H, m), 1.96 (3H, s). 13C NMR 
(101 MHz, CDCl3) δ 170.37, 165.93, 152.71, 142.86, 141.45, 136.25, 133.03, 131.15, 130.83, 
129.73, 129.70, 129.54, 128.52, 128.32, 127.40, 124.35, 124.31, 124.06, 122.78, 70.83, 53.38, 











Prepared from imine 4a and glutaric anhydride (114 mg, 1 equiv) using General Procedures B 
and C. Temp = 105 oC, time = 18 h. Purification: Flash chromatography on silica eluting with 
hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 268 mg, 80% over 2 steps, 95:5 dr. 
1H NMR (400 MHz, CDCl3) δ 7.47 to 7.05 (10H, m), 6.39 (1H, d), 6.15 to 6.09 (1H, dd), 4.92 to  
4.89 (1H, d), 3.79 (3H, s), 2.97 to 2.93 (1H, m), 2.73 to 2.61 (2H, m), 2.42 to 2.25 (2H, m). 13C 
NMR (101 MHz, CDCl3) δ 172.5, 169.3, 141.9, 135.8, 134.8, 133.3, 129.1, 128.8, 128.2, 127.7, 
127.3, 126.5, 124.4, 63.8, 52.5, 44.5, 29.9, 20.4. HRMS-EI+ (m/z): calc’d for C21H21NO3 








Prepared from imine 4c (221 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. T = 105 oC, time = 18 h. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 304 mg, 87% over 
2 steps, 95:5 dr. 1H NMR (400 MHz, CDCl3) δ 7.38 to 7.00 (9H, m), 6.41 to 6.34 (1H, d), 6.18 to 
6.10 (1H, dd), 4.90 to 4.87 (1H, dd), 3.77 (3H, s), 2.96 to 2.93 (1H, m), 2.70 to 2.61 (2H, m), 
2.41 to 2.28 (5H, m). 13C NMR (101 MHz, CDCl3) δ 172.5, 169.4, 139.3, 137.0, 135.9, 134.8, 
133.2, 130.0, 129.8, 129.3, 128.7, 128.3, 128.2, 128.1, 127.7, 127.47, 127.3, 126.7, 126.6, 124.5, 











Prepared from imine 4b (237 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. T = 105 oC, time = 18 h. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100) then 100% MeOH. Yield = 307 mg, 84% over 
2 steps, 95:5 dr. 1H NMR (400 MHz, CDCl3) δ 7.37 to 7.15 (7H, m), 6.87 (2H, d), 6.38 to 6.31 
(1H, d), 6.13 to 6.09 (1H, dd), 4.69 to 4.67 (1H, dd), 3.77 to 3.72 (6H, ss), 2.89 to 2.72 (1H, t), 
2.65 to 2.56 (2H, m), 2.39 to 2.23 (2H, m). 13C NMR (101 MHz, CDCl3) δ 172.9, 169.5, 158.4, 
135.9, 134.9, 134.7, 133.2, 129.3, 128.8, 128.7, 128.7, 128.3, 128.2, 127.6, 126.7, 126.6, 124.5, 








Prepared from imine 4d (333 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. T = 105 oC, time = 22 h. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 346 mg, 75% over 2 steps, 95:5 dr.  
1H NMR (400 MHz, CDCl3) δ 7.77 (2H, d), 7.46 to 7.23 (5H, m), 7.04 (2H, d), 6.37 to 6.33 (1H, 
d), 6.16 to 6.08 (1H, dd), 4.88 to 4.85 (1H, dd), 3.78 (3H, s), 2.95 to 2.93 (1H, m), 2.69 to 2.61 
(2H, m), 2.37 to 2.24 (2H, m). 13C NMR (101 MHz, CDCl3) δ 172.4, 169.2, 141.7, 138.5, 138.3, 
138.3, 137.7, 135.6, 135.1, 133.5, 131.3, 130.4, 129.7, 129.4, 129.2, 128.8, 128.5, 128.5, 128.4, 
127.1, 126.7, 126.6, 124.1, 123.9, 92.5, 63.7, 52.3, 44.7, 29.8, 20.6. HRMS-EI+ (m/z): calc’d for 









Prepared from imine 4g (363 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. T = 105 oC, time = 22 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50 to 0:100). Yield = 339 mg, 69% over 2 steps, 95:5 dr.  
1H NMR (400 MHz, CDCl3) δ 7.71 (2H, d), 7.28 to 7.16 (3H, m), 7.04 to 6.98 (2H, m), 6.81 
(2H, d), 6.27 (1H, d), 5.95 to 5.91 (1H, dd), 4.82 to 4.79 (1H, dd), 3.78 to 3.74 (6H, s,s), 2.93 to 
2.90 (1H, m), 2.61 to 2.57 (2H, m), 2.38 to 2.24 (2H, m). 13C NMR (101 MHz, CDCl3) δ 173.4, 
169.2, 159.8, 141.7, 138.2, 137.7, 133.0, 129.7, 129.4, 128.3,, 127.8, 127.4, 124.7, 114.16, 92.5,  








Prepared from imine 4b (337 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. T = 110 oC, time = 26 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 339 mg, 77% 
over 2 steps, 95:5 dr. 1H NMR (400 MHz, CDCl3) δ 7.36 to 7.12 (7H, m), 6.84 to 6.81 (2H, d),  
6.29 to 6.26 (1H, d), 5.91 to 5.87 (1H, dd), 4.75 to 4.70 (1H, t), 3.78 to 3.70 (6H, s,s), 3.03 to 
2.98 (1H, m), 2.27 to 2.19 (1H, dd), 2.09 to 2.03 (1H, dd), 1.41 to 1.35 (6H, ss). 13C NMR (101 
MHz, CDCl3) δ 175.6, 173.2, 158.2, 136.0, 134.9, 134.3, 133.3, 129.3, 129.2, 128.7, 128.6, 
128.2, 128.2, 128.1, 128.0, 126.6, 114.5, 64.7, 55.3, 52.1, 43.4, 38.4, 38.0, 28.4, 27.8. HRMS-









Prepared from imine 4c (221 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. T = 110 oC, time = 26 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 317 mg, 84% 
over 2 steps, 95:5 dr. 1H NMR (400 MHz, CDCl3) δ7.37 to 7.05 (9H, m), 6.29 to 6.25 (1H, d), 
5.87 to 5.85 (1H, dd), 4.78 to 4.74 (1H, t), 3.77 (3H, s), 3.03 to 2.91 (1H, m), 2.36  to 2.26 (4H, 
m), 2.09 to 1.98 (1H, dd), 1.38 to 1.26 (6H, s,s). 13C NMR (101 MHz, CDCl3) δ 175.5, 173.2, 
138.8, 136.7, 136.1, 133.3, 129.6, 129.4, 129.1, 128.5, 128.2, 127.9, 127.9, 127.2, 126.6, 126.5, 








Prepared from imine 4e (275 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. T = 110 oC, time = 36 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 302 mg, 70% 
over 2 steps, 96:4 dr. 1H NMR (400 MHz, CDCl3) δ 7.52 to 7.16 (9H, m), 6.33 (1H, d), 5.85 to 
5.82 (1H, dd), 4.85 to 4.81 (1H, t), 3.70 (3H, s), 3.07 to 2.91 (1H, m), 2.27 to 2.22 (1H, dd), 2.09 
to 2.01 (1H, dd), 1.46 (3H, s) 1.43 (3H, s). 13C NMR (101 MHz, CDCl3) δ 175.6, 172.9, 142.0, 
135.7, 134.3, 132.0, 131.4, 131.1, 129.4, 128.7, 128.6, 128.2, 127.4, 126.6, 126.4, 125.3, 125.2, 
125.2, 125.2, 124.4, 64.6, 52.2, 43.3, 38.2, 37.4, 27.9. 27.3. HRMS-EI+ (m/z): calc’d for 










Prepared from imine 4f (267 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. T = 105 oC, time = 22 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 351 mg, 83% 
over 2 steps, 96:4 dr. 1H NMR (400 MHz, CDCl3) δ 7.14 to 7.07 (4H, m), 6.83 to 6.77 (4H, m), 
6.21 to 6.17 (1H, d), 5.76 to 5.70 (1H, dd), 4.71 to 4.67 (1H, t), 3.82 to 3.68 (9H, m), 3.01 to 2.96 
(1H, m), 2.25 to 2.19 (1H, dd), 2.08 to 1.92 (1H, dd), 1.40 to 1.37 (6H, s,s). 13C NMR (101 MHz, 
CDCl3) δ 175.6, 173.3, 159.5, 158.1, 134.3, 132.8, 129.3, 129.0, 128.8, 128.6, 127.9, 127.7, 
125.9, 114.6, 114.2, 114.0, 113.9, 64.8, 55.5, 55.3, 52.1, 43.6, 38.0, 37.5, 28.4, 28.0. HRMS-EI+ 
(m/z): calc’d for C25H29NO5 423.2046; found 423.2051. 
 
 
Prepared from imine 4i (251 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. T = 105 oC, time = 18 h. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 300 mg, 79% over 2 steps, 95:5 dr.  
1H NMR (400 MHz, CDCl3) δ 7.32 to 7.12 (7H, m), 6.88 (2H, d), 6.43 (1H, s), 4.75 (1H, d), 3.77 
to 3.66 (6H, s,s), 2.87 to 2.85 (1H, m), 2.71 to 2.58 (2H, m), 2.26 to 2.20 (2H, m), 1.80 (3H, s). 
13C NMR (101 MHz, CDCl3) δ 172.9, 170.0, 158.2, 136.8, 134.5, 129.7, 128.8, 128.4, 128.2, 
126.9, 114.2, 69.6, 55.4, 52.4, 42.9, 30.4, 21.1, 15.3. HRMS-EI+ (m/z): calc’d for C23H25NO4 




Prepared from imine 4i (251 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. Temp = 110 oC, time = 36 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 300 mg, 79% 
over 2 steps, 95:5 dr. 1H NMR (400 MHz, CDCl3) δ 7.30 to 7.09 (5H, m), 7.01 to 6.96 (2H, d), 
6.78 to 6.74 (2H, d), 6.26 (1H, s), 4.68 (1H, d), 3.78 to 3.73 (6H, s,s), 3.22 to 3.16 (1H, m), 2.31 
to 2.19 (1H, dd), 2.03 to 1.97 (1H, dd), 1.74 (3H, s), 1.43 (3H, s), 1.41 (3H, s). 13C NMR (101 
MHz, CDCl3) δ 176.1, 173.3, 159.3, 136.8, 134.2, 133.8, 132.9, 131.3, 131.2, 129.3, 129.0, 
128.9, 128.8, 128.7, 128.4, 128.2, 128.1, 127.9, 127.1, 126.8, 114.5, 70.8, 55.4, 52.2, 41.78, 38.7, 
38.1, 28.6, 28.2,  27.0, 13.7. HRMS-EI+ (m/z): calc’d for C25H29NO4 407.2097; found 407.2093. 
 
 
Prepared from imine 4k (171 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 235 mg, 75%, 
98:2 dr. 1H NMR (400 MHz, MeOH) δ 11.12 (1H, br. s), 7.42 to 7.22 (5H, m), 6.53 to 6.50 (1H, 
d), 6.22 to 6.16 (1H, dd), 4.50 to 4.48 (1H, t), 2.86 to 2.81 (1H, t), 2.57 to 2.48 (1H, t), 1.80 to 
1.77 (2H, m), 1.26 to 0.53 (10H, m). 13C NMR (101 MHz, MeOH) δ 179.1, 174.7, 136.2, 132.9, 
128.3, 127.6, 126.2, 61.9, 48.2, 48.0, 48.0, 47.8, 47.8, 47.65, 47.5, 47.4, 47.3, 47.2, 47.1, 47.0, 





Prepared from imine 4l (185 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash chromatography 
on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 226 mg, 72% over 2 steps, 98:2 
dr. 1H NMR (400 MHz, CDCl3) δ 7.30 to 7.13 (5H, m), 6.30 (1H, s), 4.36 to 4.33 (1H, d), 3.69 
(3H, s), 2.88 to 2.80 (1H, dd), 2.54 to 2.30 (3H, m), 1.89 to 1.75 (5H, m), 0.96 to 0.91 (1H, m), 
0.70 to 0.51 (3H, m). 13C NMR (101 MHz, CDCl3) δ 172.8, 171.7, 136.8, 135.2, 129.1, 128.9, 
128.4, 128.2, 128.2, 128.2, 128.1, 127.0, 126.9, 66.2, 51.9, 42.3, 30.4, 28.0, 20.1, 16.4, 8.8, 5.6. 
HRMS-EI+ (m/z): calc’d for C19H23NO3 313.1678; found 313.1683. 
 
 
Prepared from imine 4l (185 mg, 1.0 mmol) and 2,2-dimethyl glutaric anhydride (142 mg, 1.0 
equiv), using General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash 
chromatography on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 239 mg, 70% 
over 2 steps, 98:2 dr. 1H NMR (400 MHz, CDCl3) δ 7.38 to 7.21 (5H, m), 6.43 (1H, s), 4.37 (1H, 
d), 3.65 (3H, s),2.89 to 2.86 (1H, m), 2.36 to 2.31 (1H, t), 1.89 to 1.77 (5H, m), 1.32 to 1.25 (6H, 
s,s), 0.91 to 0.87 (1H, m), 0.70 to 0.55 (3H, m). 13C NMR (101 MHz, CDCl3) δ 178.0, 173.6, 
137.0, 135.0, 129.7, 128.9, 128.4, 128.3, 128.2, 126.9, 68.0, 52.1, 40.8, 38.3, 37.0, 28.5, 28.1, 





Prepared from imine 4n (187 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. Temp = 100 oC, time = 12 h. Purification: Flash chromatography 
on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 258 mg, 82% over 2 steps, 95:5 
dr. 1H NMR (400 MHz, CDCl3) δ 7.57 to 7.14 (5H, m), 6.52 to  6.49 (1H, d), 6.19 to 6.07 (1H, 
dd), 5.03 to 5.01 (1H, dd), 3.78 (3H, s), 2.92 to 2.81 (1H, m), 2.53 to 2.31 (2H, m), 2.15 to 1.90 
(2H, m), 1.47 (9H, s). 13C NMR (101 MHz, CDCl3) δ 172.7, 170.6, 136.0, 133.2, 129.1, 128.7, 
128.1, 127.9, 126.4, 58.7, 58.2, 51.6, 44.7, 31.0, 28.5, 18.6. HRMS-EI+ (m/z): calc’d for 
C19H25NO3 315.1834; found 315.1839. 
 
 
Prepared from imine 4o (201 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash chromatography 
on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 250.0 mg, 76% over 2 steps, 95:5 
dr. 1H NMR (400 MHz, CDCl3) δ 7.37 to 7.17 (5H, m), 6.39 (1H, s), 4.71 (1H, d), 3.76 (3H, s), 
2.92 to 2.88 (1H, m), 2.55 to 2.32 (3H, m), 2.23 to 1.82 (4H, m), 1.49 (9H, s). 13C NMR (101 
MHz, CDCl3) δ 173.0, 170.5, 136.9, 129.0, 128.8, 128.2, 127.6, 127.2, 126.9, 62.3, 58.6, 55.3, 







Prepared from imine 4q (187 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash chromatography 
on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 239.6 mg, 76% over 2 steps, 
90:10 dr. 1H NMR (400 MHz, CDCl3) δ 7.37 to 7.21 (5H, m), 6.39 (1H, s), 4.55 to 4.37 (2H, m), 
3.77 (3H, s), 2.88 to 2.82 (1H, m), 2.63 to 2.37 (2H, m), 2.08 to 1.76 (5H, m), 1.41 to 1.26 (6H, 
m). 13C NMR (101 MHz, CDCl3) δ 172.82, 170.14, 137.03, 136.84, 136.42, 129.88, 128.87, 
127.88, 126.98, 125.56, 61.80, 55.02, 47.93, 41.67, 30.38, 20.95, 20.16, 19.52, 18.86. HRMS-
EI+ (m/z): calc’d for C19H25NO3 315.1834; found 315.1839. 
 
 
Prepared from imine 4v (185 mg, 1.0 mmol) and glutaric anhydride (114 mg, 1.0 equiv), using 
General Procedures B and C. Temp = 100 oC, time = 18 h. Purification: Flash chromatography 
on silica eluting with hexane/EtOAc (50:50 to 0:100). Yield = 235 mg, 75% over 2 steps, 95:5 
dr. 1H NMR (400 MHz, CDCl3) δ 7.38 to 7.02 (5H, m), 6.34 (1H, s), 5.82 to 5.72 (1H, m), 5.13 
to 5.05 (2H, m), 4.75 to 4.70 (1H, dd), 4.38 (1H, d), 3.72 to 3.60 (4H, m), 3.28 to 3.21 (1H, dd), 
2.87 to 2.80 (1H, m), 2.49 to 2.20 (2H, m), 2.03 to 1.69 (5H, m). 13C NMR (101 MHz, CDCl3) δ 
172.8, 169.6, 136.7, 134.4, 132.7, 129.1, 128.9, 128.3, 127.0, 118.0, 65.2, 52.2, 46.3, 42.6, 30.1, 















Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 290.8 mg, 88%.
 1
H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 
7.0 Hz, 2H), 7.28 (dt, J = 14.9, 7.6 Hz, 3H), 7.21 (d, J = 7.4 Hz, 1H), 6.50 (d, J = 16.0 Hz, 1H), 
6.28 (dd, J = 16.0, 7.3 Hz, 1H), 4.69 (dd, J = 7.7, 2.8 Hz, 1H), 3.73 (s, 3H), 3.62 to 3.49 (m, 3H), 
2.44 (s, 3H), 1.40 (s, 9H). 
13
C NMR (101 MHz, CDCl
3
) δ 171.3, 168.0, 136.2, 131.4, 130.9, 
130.2, 130.0, 129.2, 128.7, 128.1, 128.0, 126.6, 126.0, 67.1, 58.3, 58.1, 55.6, 51.7, 41.7, 28.4. 











Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 285.9 mg, 83%. 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 
7.5 Hz, 1H), 7.47 to 7.16 (m, 4H), 6.40 (s, 1H), 4.52 (s, 1H), 3.74 (s, 3H), 3.64 to 3.41 (m, 1H), 
2.44 (s, 2H), 1.94 (s, 3H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 172.0, 168.6, 137.3, 
130.0, 129.6, 129.3, 129.0, 128.8, 128.5, 128.3, 127.8, 127.4, 127.0, 126.8, 65.1, 63.3, 58.4, 55.7, 
51.7, 41.8, 27.9, 16.1. 
 













Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 287.9 mg, 79%.
 1
H NMR (400 MHz, CDCl3) δ 7.30 (m, 
2H), 6.93 to 6.72 (m, 2H), 6.43 (d, J = 16.0 Hz, 1H), 6.13 (dd, J = 16.0, 7.5 Hz, 1H), 4.66 (dd, J 
= 7.5, 2.6 Hz, 1H), 3.87 to 3.64 (m, 8H), 3.50 (dt, J = 29.0, 17.1 Hz, 3H), 2.44 (s, 3H), 1.39 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 171.4, 168.0, 159.5, 130.8, 130.3, 129.0, 128.6, 128.0, 
127.8, 114.1, 67.2, 58.3, 58.0, 55.6, 55.4, 51.6, 41.7, 28.4. HRMS-EI+ (m/z): calc’d for 










Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 268.9 mg, 85%.
 1
H NMR (400 MHz, CDCl3) δ 7.43 to 7.12 
(m, 5H), 6.52 (d, J = 16.0 Hz, 1H), 6.33 (dd, J = 16.0, 7.9 Hz, 1H), 4.52 (h, J = 7.1 Hz, 1H), 4.34 
(d, J = 7.7 Hz, 1H), 4.07 (q, J = 7.1 Hz, 1H), 3.69 (s, 3H), 3.62 to 3.42 (m, 2H), 2.44 (s, 3H), 
1.16 (dt, J = 40.7, 6.7 Hz, 7H). 13C NMR (101 MHz, CDCl3) δ 170.9, 166.8, 136.2, 131.7, 130.5, 
129.8, 129.0, 128.7, 128.2, 128.1, 126.9, 66.6, 57.4, 54.5, 51.7, 46.5, 46.1, 42.1, 21.1, 20.6, 19.7. 














Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 306.2 mg, 78%.
 1
H NMR (400 MHz, CDCl3) δ 7.41 (dt, J = 
13.6, 7.1 Hz, 4H), 7.29 to 7.15 (m, 8H), 6.27 (d, J = 9.4 Hz, 1H), 4.47 (h, J = 9.3, 8.1 Hz, 1H), 
4.36 (d, J = 9.4 Hz, 1H), 3.63 (d, J = 16.2 Hz, 3H), 3.53 (d, J = 17.3 Hz, 3H), 2.49 (s, 3H), 1.04 
(d, J = 6.9 Hz, 3H), 0.71 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.6, 166.6, 142.3, 
141.5, 138.8, 130.1, 130.0, 129.7, 129.0, 128.9, 128.8, 128.7, 128.6, 128.4, 128.1, 127.9, 127.8, 
66.6, 54.5, 54.2, 53.4, 51.8, 51.6, 45.7, 42.2, 20.7, 19.1. HRMS-EI+ (m/z): calc’d for 
C24H28N2O3 392.2100; found 392.4907. 
 
Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 267.6 mg, 81%. 1H NMR (400 MHz, CDCl3) δ 7.34 (p, J = 
6.8, 5.5 Hz, 3H), 7.29 to 7.18 (m, 3H), 6.43 (s, 1H), 4.67 to 4.50 (m, 1H), 4.27 to 4.21 (m, 1H), 
3.73 (s, 3H), 3.71 to 3.54 (m, 2H), 3.54 to 3.35 (m, 1H), 2.46 (d, J = 16.5 Hz, 3H), 1.95 (d, J = 
6.1 Hz, 3H), 1.13 (d, J = 6.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 171.4, 167.7, 137.7, 137.5, 
137.2, 129.8, 129.0, 128.90, 128.7, 128.5, 128.3, 128.1, 127.0, 126.8, 65.5, 62.1, 54.6, 54.3, 53.7, 
52.1, 51.8, 51.6, 46.5, 45.9, 43.3, 42.0, 41.8, 29.76, 20.0, 19.8, 19.4, 18.8. 
 
HRMS-EI+ (m/z): 













Prepared from 4-methylmorpholine-2,6-dione (129 mg, 1.0 equiv) using General Procedures B & 
C. T = 100 oC, time = 24 h. Yield = 266.3 mg, 70%. 1H NMR (400 MHz, CDCl3) δ 7.37 to 7.25 
(m, 4H), 7.29 to 7.15 (m, 2H), 6.92 to 6.72 (m, 2H), 6.72 (t, J = 2.3 Hz, 1H), 6.44 (dd, J = 15.9, 
8.2 Hz, 1H), 6.33 (d, J = 15.9 Hz, 1H), 4.59 (dd, J = 8.3, 2.7 Hz, 1H), 3.83 (s, 3H), 3.71 (d, J = 
9.9 Hz, 4H), 3.67 to 3.57 (m, 2H), 2.59 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 170.8, 166.7, 
160.2, 141.9, 136.0, 133.6, 130.2, 130.0, 129.7, 129.1, 128.7, 128.2, 127.2, 126.8, 126.7, 120.0, 
113.5, 66.0, 64.9, 55.6, 55.3, 54.9, 52.0, 42.6. HRMS-EI+ (m/z): calc’d for C22H24N2O4 













SYNTHETIC APPLICATIONS OF ALLYLIC LACTAMOYL ESTERS 
 Access to a highly functionalized and diastereoselective common intermediate is the 
ultimate goal as a DOS strategy. Reaching this intermediate can allow access to various motifs 
through further functionalizations. Through the modular and cost-effective synthesis of our 
allylic lactamoyl acid/ester 1, we envision being able to synthesize polycyclic motifs 2-9 through 
various cyclization methods as seen in Figure 3-1. 
 




3.1: Progress toward the synthesis of macrocyclic enamidynes 
Macrocycles are eight or more membered ring systems, some of which constitute the core 
of pharmaceuticals and natural products. Due to their large size and multiple positions for 
functionalization, the synthesis of these macrocycles have become one of the most expansive 
fields in synthetic chemistry. However, macrocycles tend to be unstable due to the large size 
allowing for expanding and contracting of bonds. Additionally, their construction from acylic 
precursors can be rendered difficult due to high entropic and enthalpic costs. Indeed, common 
approaches to functionalized N-macrocycles such as rhazilinam almost always fearing a ring-
closing metathesis step. Herein, we propose a synthesis of novel macrocyclic enamidynes 7/8 
that utilizes in-house allylic lactamoyl esters of type 1 (Scheme 3-1). It is theorized that 
Sonagashira cross-coupling of iodoarylated lactam 1a with terminal alkynes, which bear a 
pendant leaving group would afford 10. Subsequent lithiation-cyclization of Williamson-
etherification of 10 would set the stage for accessing 7 and 11, respectively. It is recognized that 
geometrical constraints could prevent macrocyclization. In that scenario, the reduction of the 





Scheme 3-1. Synthetic approach to macrocyclic enamidynes. 
Studies toward the assembly of the proposed macrocyclic architectures began with 
attempts to successfully couple 1a and terminal alkynes using conditions developed by another 
graduate student in our group (on a different substrate). In the event, it was found that coupling 
of iodoarylated lactams with electronically diverse alkynes, under palladium and copper catalyst 
proceeded satisfactorily and delivered the internal alkynes depicted in Scheme 3-2. These 


















































Scheme 3-2.  Sonogashira cross-coupling of para-iodoarylated lactams. 
3.2: Regio- and diasteroselective one-pot hydro(amino)alkylation of lactamoyl esters 
During the course of these studies, we found that lactamoyl esters of type 1 can react 
chemoselectively with organometallic reagents to afford tertiary alcohols such as A,193 which 
were subsequently converted to bicyclic motifs such as B and C by other researchers in our 




Scheme 3-3.  Previous work from our group on chemoselective addition of organometallic 
reagents to lactamoyl esters. 
Attempts to extend this mode of reactivity to piperazinonates have led to the surprising 
but exciting discovery that in the presence of excess allylmagnesium bromide, diastereoselective 
formation of bicycles of type 12 (Scheme 3-4) is achievable. 
 
Scheme 3-4.  Preliminary evidence for the hydroaminoalkylation of 1 
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Optimization results have since revealed that the reaction works better when the C2 
substituent is an aryl group rather than a vinyl groups (Scheme 3-5). The reason for this is not 
clear at this point. Nonetheless, this groundbreaking result highlights the first example of 
hydroaminoalkylation in the absence of a transition metal. The reaction takes place with branced 
regioselectivity and the diastereoselectivity is impeccable. During the process, three new 
stereocenters are created with complete stereocontrol. The relative configuration of the product is 
not fully established at this point. 
 
Scheme 3-5.  Hydroaminoalkylation of benzylic lactamoyl esters 
Our mechanistic hypothesis is presented in Figure 3-2. Reaction of two equivalents of 
allylmagnesium bromide with 13 delivers a tertiary alkoxide, while a third equivalent of the 
Grignard reagents enolizes the amide motif, giving rise to 15. Subsequent intramolecular 
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hydroalkylation affords intermediate 16, which gets protonated during workup to afford bicycle 
14. 
 
Figure 3-2. Mechanistic rationale for hydroalkylation of 13. 
The possibility exists that the reaction proceeds via metallaazirindine 18 followed by 




Figure 3-3. Alternative mechanistic rationale for hydroaminoalkylation of 13. 
3.3: Conclusion 
The synthetic utility of the cycloadducts prepared using methodology derived herein has 
been exemplified through the achievement of some sagacious cross-coupling events, which have 
paved the way for eventual construction of alkyne-bearing N-macrocycles. Importantly, we have 
found an unprecedented example of a hydroamino alkylation that is transition metal-free and 
occurs at room temperature. Details of the transformation are being fletched out by some other 





S3: Supporting Information for Chapter 3 
S3-1: General Experimental Information and Procedures  
All experiments involving air and moisture sensitive reagents, such as palladium 
precatalysts and organolithium reagents, were carried out under an inert atmosphere of nitrogen 
and using freshly distilled solvents. Column chromatography was performed on silica gel (230-
400 mesh). Thin-layer chromatography (TLC) was performed using Silicycle SiliaplateTM glass 
backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) and visualized using UV (254 
nm) or CAM, p-anisaldehyde, or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, and DEPT-
135 NMR, COSY 45, HMQC, and NOESY spectra were acquired using DMSO-d6, CD3OD or 
CDCl3 as solvent at room temperature. Chemical shifts are quoted in parts per million (ppm). 
HRMS-EI+ data were obtained using either electronspray ionization (ESI) or electron impact (EI) 
techniques. High-resolution ESI was obtained on an LTQ-FT (ion trap; analyzed using 
Excalibur). High resolution EI was obtained on an Autospec (magnetic sector; analyzed using 
MassLynx). 
 
General Procedure D: Sonogashira cross-coupling with iodoarylated lactams 
To the crude lactamoyl ester (1.0 mmol) dissolved in Et3N:DMF (1:5 mL) was added 
Pd(PPh3)2Cl2 (5 mol%) and copper iodine (5 mol%) under nitrogen atmosphere. After initial 
mixing, 5-chloro-1-pentyne (1.1 mmol) is injected. The reaction mixture was stirred for 12 to 24 
h (TLC monitoring). After complete conversion, it was diluted with water and extracted with 
EtOAc (2×20 mL). The combined organic extracts were washed with brine, dried over Na2SO4 
and concentrated in vacuo to give the desired alkynyl-arylated lactam. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with Hexane/EtOAc (1:2). 
 
General Procedure E: Grignard Additon 
To the crude lactamoyl ester (1.0 mmol) dissolved in freshly distilled THF (5 mL), was 
slowly added methyl magnesium bromide (2.0 mL, 1.0 M solution in THF, 3 equiv) under 
nitrogen at ‒78 °C. After complete consumption of the ester (as indicated by TLC and GC-MS), 
the mixture quenched by slow addition of sat. aq NH4Cl. The mixture was diluted with Et2O. 
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The layers were separated and the aqueous layer was extracted twice with EtOAc. The combined 
organic layers were dried over Na2SO4 for 30 min, filtered, and concentrated under reduced 
pressure to give the desired product. Purification: Flash chromatography on silica (pretreated 
with 1% Et3N) eluting with Hexane/EtOAc (1:2). 
 






Prepped from aryl iodide 7d2 (461 mg, 1 mmol, 1.0 equiv) and 5-chloro-1-pentyne (0.212 mL, 2 
mmol, 2 equiv), using General Procedure D. Yield = 356.9 mg, 82%. 1H NMR (400 MHz, 
CDCl3) δ 7.40 to 7.16 (9H, m), 6.41 to 6.37 (1H, d), 6.18 to 6.06 (1H, dd), 4.89 to 4.86 (1H, dd), 
3.78 to 3.63 (5H, m), 2.93 to 2.86 (2H, m), 2.65 to 2.51 (4H, m), 2.34 to 2.18 (2H, m), 2.03 to 
1.97 (2H, m). 13C NMR (101 MHz, CDCl3) δ 172.4, 169.2, 141.3, 135.7, 134.9, 133.4, 132.3, 
128.7, 128.4, 127.5, 127.3, 126.7, 124.3, 122.5, 88.7, 81.1, 63.6, 52.5, 44.7, 43.8, 31.4, 29.7, 










Prepped from α-methyl derivative of aryl iodide 7d2 (475 mg, 1 mmol, 1.0 equiv) and 
ethynyltrimethylsilane (0.277 mL, 2 mmol, 2 equiv), using General Procedure D. Yield = 334.2 
mg, 75%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.49 – 7.32 (m, 3H), 7.30 (t, J = 7.5 Hz, 2H), 
7.23 (dd, J = 7.7, 5.6 Hz, 2H), 7.10 (d, J = 7.5 Hz, 2H), 6.41 (s, 1H), 4.79 (d, J = 5.7 Hz, 1H), 
3.76 (s, 3H), 3.67 (d, J = 9.4 Hz, 1H), 3.06 – 2.92 (m, 1H), 2.75 – 2.55 (m, 1H), 2.41 (dt, J = 
15.4, 7.1 Hz, 1H), 2.24 (dtt, J = 9.3, 6.7, 3.2 Hz, 1H), 1.92 – 1.77 (m, 2H), 0.23 (d, J = 4.4 Hz, 
9H). 13C NMR (101 MHz, CDCl3) δ 172.8, 169.7, 141.8, 136.6, 134.3, 132.7, 130.0, 129.0, 
128.8, 128.6, 128.3, 127.6, 127.3, 127.1, 121.8, 104.6, 94.7, 69.1, 52.5, 42.8, 30.5, 21.0, 20.6, 
15.3, 0.1. HRMS-EI+ (m/z): calc’d for C27H31NO3Si 445.2073; found 445.6254. 
 
 
Prepped from aryl iodide made by coworker (477 mg, 1 mmol, 1.0 equiv) and 
ethynyltrimethylsilane (0.277 mL, 2 mmol, 2 equiv), using General Procedure D. Yield = 376.0 
mg, 84%. 
1
H NMR (400 MHz, Chloroform-d) δ 7.54 – 7.41 (m, 2H), 7.31 (q, J = 7.3 Hz, 2H), 










(m, 2H), 4.45 (d, J = 17.3 Hz, 1H), 3.85 (s, 3H), 1.93 (s, 3H), 0.25 (d, J = 5.1 Hz, 10H). 13C 
NMR (101 MHz, CDCl3) δ 169.7, 166.2, 139.8, 136.3, 132.9, 132.8, 130.7, 129.0, 128.4, 128.3, 
127.3, 126.3, 104.3, 95.2, 75.0, 67.6, 65.7, 53.0, 15.0, 0.1. HRMS-EI+ (m/z): calc’d for 









Prepped from aryl iodide made by coworker (477 mg, 1 mmol, 1.0 equiv) and 
cyclopropylacetlene (0.2 mL, 2 mmol, 2 equiv) using General Procedure D. Yield = 249.3 mg, 
75%. 1H NMR (400 MHz, Chloroform-d) δ 7.31 (td, J = 19.4, 18.3, 6.9 Hz, 7H), 7.14 (d, J = 8.0 
Hz, 2H), 6.43 (d, J = 15.9 Hz, 1H), 6.28 (dd, J = 15.8, 7.9 Hz, 1H), 4.80 (dd, J = 8.0, 2.7 Hz, 
1H), 4.69 (d, J = 17.3 Hz, 1H), 4.57 (d, J = 2.7 Hz, 1H), 4.52 – 4.41 (m, 1H), 3.86 (s, 2H), 3.78 
(d, J = 14.3 Hz, 1H), 1.42 (tt, J = 8.8, 5.0 Hz, 1H), 0.92 – 0.73 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 169.6, 165.6, 138.9, 135.4, 134.7, 132.6, 128.8, 128.6, 126.7, 124.5, 94.5, 75.8, 75.1, 











Prepped from aryl iodide made by coworker (477 mg, 1 mmol, 1.0 equiv) and 1-
ethynylcyclohexene (0.2 mL, 2 mmol, 2 equiv), using General Procedure D. Yield = 355.3 mg, 
76%. 1H NMR (400 MHz, Chloroform-d) δ 7.41 (d, J = 8.1 Hz, 3H), 7.29 (d, J = 14.0 Hz, 3H), 
7.27 – 7.15 (m, 3H), 6.44 (d, J = 15.9 Hz, 1H), 6.29 (dd, J = 15.8, 7.8 Hz, 1H), 6.20 (q, J = 5.7, 
4.1 Hz, 1H), 4.85 – 4.78 (m, 1H), 4.69 (d, J = 17.2 Hz, 1H), 4.58 (d, J = 2.7 Hz, 1H), 4.46 (d, J = 
17.3 Hz, 1H), 3.83 (s, 3H), 2.23 – 2.07 (m, 4H), 1.70 – 1.53 (m, 4H). 13C NMR (101 MHz, 
CDCl3) δ 169.6, 165.7, 139.2, 135.9, 135.7, 134.6, 132.4, 132.3, 128.8, 128.6, 126.7, 124.6, 
120.6, 92.2, 86.1, 75.7, 65.5, 63.1, 52.9, 29.2, 25.8, 22.4, 21.6. HRMS-EI+ (m/z): calc’d for 




S3-3: Allylic Grignard Addition to lactamoyl esters 
 
Prepped from allylic ketopiperazine 8a2 (330.2 mg, 1 mmol, 1.0 equiv) and allyl magnesium 
bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using General Procedure E. 
Preliminary data. 
1
H NMR (400 MHz, CDCl3) δ 7.33 to 7.28 (m, 5H), 6.50 (d, J = 16.0, 1H), 
6.12 (dd, J = 16.0, 6.5 Hz, 1H), 6.03 to 5.83 (m, 2H), 5.22 to 5.09 (m, 4H), 4.69 (d, J = 6.5 Hz, 
1H), 3.64 (d, J = 15.8 Hz, 1H), 3.34 (d, J = 15.8 Hz, 1H), 2.80 (s, 1H), 2.50 to 2.20 (m, 8H), 1.42 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 168.9, 136.2, 134.3, 134.2, 133.7, 132.7, 131.7, 131.1, 
130.8, 130.3, 128.8, 128.6, 128.1, 127.7, 127.2, 126.6, 126.5, 126.4, 125.6, 118.7, 118.4, 76.4, 









Prepped from allylic ketopiperazine 8d2 (346.2 mg, 1 mmol, 1.0 equiv) and allyl magnesium 
bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using General Procedure E. 
Preliminary data. 
1
H NMR (400 MHz, CDCl3) δ 7.27 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.1 Hz, 
2H), 6.40 (d, J = 15.9 Hz, 1H), 6.02 (dd, J = 15.9, 7.2 Hz, 1H), 5.90 (tq, J = 16.5, 7.7 Hz, 2H), 
5.14 (td, J = 17.0, 15.4, 7.9 Hz, 4H), 4.48 (dq, J = 13.5, 6.8 Hz, 1H), 4.40 (d, J = 7.3 Hz, 1H), 
3.81 (s, 4H), 3.31 (d, J = 16.7 Hz, 1H), 2.80 (s, 1H), 2.62 (s, 3H), 2.33 (dddd, J = 59.9, 27.3, 
14.2, 7.3 Hz, 5H), 1.31 (d, J = 6.8 Hz, 3H), 1.23 (q, J = 7.2, 6.1 Hz, 3H). 13C NMR (101 MHz, 











118.5, 114.2, 68.7, 56.6, 55.4, 54.8, 48.2, 47.9, 47.8, 41.8, 41.5, 41.1, 21.1, 20.8, 20.1. HRMS-



















Prepped from allylic ketopiperazine 8c2 (360.2 mg, 1 mmol, 1.0 equiv) and allyl magnesium 
bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using General Procedure E. Complex 









Prepped from aryl ketopiperazine (290.2 mg, 1 mmol, 1.0 equiv. made via General Procedure A-
C) and allyl magnesium bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using 
General Procedure E. Yield = 284.3 mg, 83%. 1H NMR (400 MHz, Chloroform-d) δ 7.38 – 7.19 
(m, 5H), 6.01 (tt, J = 17.2, 7.3 Hz, 1H), 5.28 – 5.18 (m, 2H), 4.35 (s, 1H), 3.78 (s, 1H), 3.39 (h, J 
= 6.7 Hz, 1H), 3.11 (d, J = 4.6 Hz, 1H), 2.75 (s, 1H), 2.54 (s, 3H), 2.51 – 2.41 (m, 1H), 2.30 (dt, 
J = 13.6, 6.3 Hz, 1H), 1.67 (dd, J = 13.9, 4.1 Hz, 1H), 1.42 (d, J = 6.8 Hz, 3H), 1.30 – 1.15 (m, 
4H), 1.00 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.3, 143.0, 133.0, 128.5, 127.4, 
127.3, 118.8, 72.3, 68.7, 65.5, 60.4, 52.6, 44.3, 43.5, 38.6, 29.7, 21.3, 19.4, 18.2. HRMS-EI+ 












Prepped from aryl ketopiperazine (320.2 mg, 1 mmol, 1.0 equiv. made via General Procedure A-
C) and allyl magnesium bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using 
General Procedure E. Yield = 324.1 mg, 87%. 1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 
2H), 6.86 (d, J = 8.3 Hz, 2H), 6.01 (dq, J = 16.4, 7.6 Hz, 1H), 5.35 – 5.27 (m, 1H), 5.28 – 5.19 
(m, 1H), 4.32 (s, 1H), 3.80 (s, 3H), 3.43 (dq, J = 13.6, 7.2 Hz, 1H), 3.13 (d, J = 4.8 Hz, 1H), 2.74 
(s, 1H), 2.57 (s, 3H), 2.48 (t, J = 6.2 Hz, 2H), 2.31 (dt, J = 12.4, 6.3 Hz, 1H), 1.67 (dd, J = 13.9, 
4.2 Hz, 2H), 1.42 (d, J = 6.9 Hz, 3H), 1.30 – 1.14 (m, 5H), 1.01 (d, J = 6.9 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.3, 158.7, 134.8, 132.9, 128.5, 118.8, 113.9, 72.3, 68.8, 65.5, 59.9, 55.3, 












Prepped from aryl ketopiperazine (304.4 mg, 1 mmol, 1.0 equiv. made via General Procedure A-
C) and allyl magnesium bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using 
General Procedure E. Yield = 278.1 mg, 78%. 1H NMR (400 MHz, CDCl3) δ 7.34 (d, J = 7.7 
Hz, 2H), 7.32 to 7.17 (m, 3H), 6.18 to 6.02 (m, 1H), 5.35 to 5.24 (m, 2H), 3.42 (s, 1H), 3.13 (d, J 
= 4.3 Hz, 1H), 2.71 (s, 1H), 2.49 (td, J = 14.2, 6.9 Hz, 2H), 2.42 (s, 3H), 2.37 to 2.29 (m, 1H), 
1.66 (dd, J = 14.0, 4.4 Hz, 1H), 1.56 to 1.43 (m, 1H), 1.37 (s, 9H), 0.98 (d, J = 6.9 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 169.5, 144.7, 133.2, 128.7, 128.0, 127.5, 127.3, 127.1, 126.4, 118.9, 
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118.7, 72.6, 69.2, 67.1, 59.3, 58.2, 44.4, 44.1, 40.0, 29.8, 29.1, 28.9, 28.5, 28.4, 18.3. HRMS-










Prepped from aryl ketopiperazine (334.2 mg, 1 mmol, 1.0 equiv. made via General Procedure A-
C) and allyl magnesium bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using 
General Procedure E. Yield = 328.5 mg, 85%.
 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 1H), 6.91 
to 6.78 (m, 3H), 6.08 (dt, J = 16.7, 9.0 Hz, 1H), 5.34 to 5.22 (m, 2H), 4.71 (s, 1H), 3.79 (s, 4H), 
3.12 (d, J = 4.2 Hz, 1H), 2.68 (s, 1H), 2.49 (dt, J = 15.6, 7.6 Hz, 1H), 2.43 (s, 3H), 2.37 to 2.27 
(m, 1H), 1.65 (dd, J = 14.2, 4.4 Hz, 1H), 1.55 to 1.42 (m, 2H), 1.38 (s, 9H), 1.34 to 1.21 (m, 3H), 
0.98 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.5, 158.6, 136.5, 134.3, 133.8, 
133.2, 127.5, 118.9, 118.6, 114.0, 113.3, 72.5, 71.8, 69.3, 67.1, 59.2, 58.7, 58.4, 57.7, 56.3, 55.3, 












Prepped from aryl ketopiperazine (338.2 mg, 1 mmol, 1.0 equiv. made via General Procedure A-
C) and allyl magnesium bromide solution (2.0 mL, 1.0 M in diethyl ether, 3 equiv), using 
General Procedure E. Yield = 277.3 mg, 71%. 1H NMR (400 MHz, CDCl3) δ 7.37 (q, J = 7.0, 
6.3 Hz, 2H), 7.35 to 7.24 (m, 4H), 7.16 (dd, J = 6.5, 3.0 Hz, 2H), 5.86 (dd, J = 14.0, 6.5 Hz, 2H), 
5.12 (d, J = 10.4 Hz, 1H), 5.00 (dd, J = 30.0, 13.4 Hz, 1H), 3.78 (s, 1H), 3.41 (d, J = 13.8 Hz, 
1H), 3.21 (d, J = 4.7 Hz, 1H), 2.81 (s, 1H), 2.50 (s, 3H), 2.27 (dt, J = 12.5, 6.0 Hz, 1H), 2.05 (s, 
3H), 1.97 (dd, J = 14.4, 7.5 Hz, 1H), 1.41 (dd, J = 14.1, 4.2 Hz, 1H), 1.03 (d, J = 7.0 Hz, 3H). 
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13C NMR (101 MHz, CDCl3) δ 168.8, 141.1, 136.9, 133.0, 129.7, 128.8, 128.6, 128.5, 128.2, 
128.1, 127.4, 118.5, 72.0, 68.6, 65.0, 57.2, 47.1, 44.5, 42.9, 38.4, 29.8, 18.1. HRMS-EI+ (m/z): 
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Appendix A: Spectral Data for Chapter 2 
 




Spectrum 1-2: 13C NMR spectrum of 5a1. 
 




Spectrum 1-4: GC spectrum of 5a2. 
 








Spectrum 1-7: 13C NMR spectrum of 5a2. 
 




Spectrum 1-9: 1H NMR spectrum of 5b1. 
 




Spectrum 1-11: DEPT-135 NMR spectrum of 5b1. 
 




Spectrum 1-13: MS spectrum of 5b2. 
 




Spectrum 1-15: 13C spectrum of 5b2. 
 




Spectrum 1-17: 1H spectrum of 5c1. 
 




Spectrum 1-19: DEPT-135 spectrum of 5c1. 
 




Spectrum 1-21: MS spectrum of 5c2. 
 




Spectrum 1-23: 13C NMR spectrum of 5c2. 
 




Spectrum 1-25: 1H NMR spectrum of 5d1. 
 




Spectrum 1-26: DEPT-135 NMR spectrum of 5d1. 
 




Spectrum 1-28: 13C NMR spectrum of 5d2. 
 




Spectrum 1-30: 1H NMR spectrum of 5e1. 
 




Spectrum 1-32: DEPT-135 NMR spectrum of 5e1. 
 





Spectrum 1-34: 13C NMR spectrum of 5f1. 
 




Spectrum 1-36: 1H NMR spectrum of 5g1. 
 




Spectrum 1-38: DEPT-135 NMR spectrum of 5g1. 
 




Spectrum 1-40: 13C NMR spectrum of 5h2 major and minor. 
 





Spectrum 1-42: GC spectrum of 5i2 major and minor. 
 
 




Spectrum 1-44: 1H NMR spectrum of 5i2 major and minor. 
 




Spectrum 1-46: DEPT-135 NMR spectrum of 5i2 major and minor. 
 




Spectrum 1-48: MS spectrum of 5j2 major.  
 





Spectrum 1-50: 13C NMR spectrum of 5j2 major and minor. 
 





Spectrum 1-52: GC spectrum of 5k2. 
 




Spectrum 1-54: 1H NMR spectrum of 5k2. 
 




Spectrum 1-56: DEPT-135 spectrum of 5k2. 
 




Spectrum 1-58: 13C NMR spectrum of 5l2. 
 




Spectrum 1-60: GC spectrum of 5m2 major and minor. 
 
 





Spectrum 1-62: 1H NMR spectrum of 5m2 major and minor. 
 




Spectrum 1-64: DEPT-135 NMR spectrum of 5m2 major and minor. 
 




Spectrum 1-66: 13C NMR spectrum of 5n1. 
 




Spectrum 1-68: GC spectrum of 5n2 major and minor. 
 




Spectrum 1-70: 1H NMR spectrum of 5n2 major. 
 




Spectrum 1-72: DEPT-135 NMR spectrum of 5n2 major. 
 




Spectrum 1-74: 13C NMR spectrum of 5o1. 
 




Spectrum 1-76: GC spectrum of 5o2. 
 




Spectrum 1-78: 1H NMR spectrum of 5o2. 
 




Spectrum 1-80: DEPT-135 NMR spectrum of 5o2. 
 




Spectrum 1-82: 13C NMR spectrum of 5p1. 
 




Spectrum 1-84: GC spectrum of 5p2 major and minor. 
 




Spectrum 1-86: 1H NMR spectrum of 5p2. 
 




Spectrum 1-88: DEPT-135 NMR spectrum of 5p2. 
 




Spectrum 1-90: DEPT-135 NMR spectrum of 5q1 major and minor. 
 




Spectrum 1-92: MS spectrum of 5r2 major. 
 




Spectrum 1-94: 13C NMR spectrum of 5r2 major. 
 













Spectrum 1-96: 1H NMR spectrum of 6b2’. 
 




Spectrum 1-98: DEPT-135 NMR spectrum of 6b2’. 
 




Spectrum 1-100: MS spectrum of 6b2’. 
 




Spectrum 1-102: 13C NMR spectrum of 6c2’. 
 








Spectrum 1-106: 1H NMR spectrum of 6d2’. 
 




Spectrum 1-108: DEPT-135 NMR spectrum of 6d2’. 
 




Spectrum 1-110: 13C NMR spectrum of 6e2’. 
 




Spectrum 1-112: 1H NMR spectrum of 6f2’. 
 




Spectrum 1-114: DEPT-135 NMR spectrum of 6f2’. 
 




Spectrum 1-116: 13C NMR spectrum of 6b2. 
 




Spectrum 1-118: 1H NMR spectrum of 6c2. 
 




Spectrum 1-120: DEPT-135 NMR spectrum of 6c2. 
 




Spectrum 1-122: 13C NMR spectrum of 6g1. 
 




Spectrum 1-124: 1H NMR spectrum of 61H. 
 




Spectrum 1-126: DEPT-135 NMR spectrum of 61H. 
 




Spectrum 1-128: 13C NMR spectrum of 6f1. 
 




Spectrum 1-130: 1H NMR spectrum of 6i1. 
 




Spectrum 1-132: DEPT-135 NMR spectrum of 6i1. 
 




Spectrum 1-134: 1H NMR spectrum of 6j2. 
 




Spectrum 1-136: DEPT-135 spectrum of 6j2. 
 




Spectrum 1-138: MS spectrum of 7a2. 
 
 
Spectrum 1-139: 1H NMR spectrum of 7a2. 
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Spectrum 1-140: 13C NMR spectrum of 7a2. 
 




Spectrum 1-142: MS spectrum of 7b2. 
 
 




Spectrum 1-144: 13C NMR spectrum of 7b2. 
 
 













Spectrum 1-148: DEPT-135 NMR spectrum of 7c1. 
 
 




Spectrum 1-150: 13C NMR spectrum of 7c2. 
 





















































































































































































































































































































































































































Spectrum 1-239: 13C NMR spectrum of 8a2 (zoomed-in spectrum included). 
 
 






































































Spectrum 1-255: DEPT-135 NMR spectrum of 8f2. 
 




















Appendix B: Spectral Data for Chapter 3 
 
Spectrum 2-1: GC spectrum of 10a1.  
 






Spectrum 2-3: 13C NMR spectrum of 10a1.  
 







Spectrum 2-5: 1H NMR spectrum of 10a2. 
 









Spectrum 2-8: 1H NMR spectrum of 10a3. 
 




Spectrum 2-10: DEPT-135 NMR spectrum of 10a3. 
 




Spectrum 2-12: 13C NMR spectrum of 10a4. 
 





Spectrum 2-14: 1H NMR spectrum of 10a5. 
 




Spectrum 2-16: DEPT-135 NMR spectrum of 10a5. 
 










Spectrum 2-19: DEPT-135 NMR spectrum of 11a. 
 




Spectrum 2-21: 13C NMR spectrum of 11b. 
 




Spectrum 2-23 and 2-24: GC and MS spectra of 12 (extracted from mixture with 11c).  
 







Spectrum 2-26: DEPT-135 NMR spectrum of 12 (extracted from mixture with 11c). 
 




Spectrum 2-28: 13C NMR spectrum of 13a. 
 




Spectrum 2-30: 1H NMR spectrum of 13b. 
 




Spectrum 2-32: DEPT-135 NMR spectrum of 13b. 





Spectrum 2-34: 13C NMR spectrum of 13c. 
 




Spectrum 2-37 and 2-38: GC and MS spectra of 13d. 
 




Spectrum 2-40: 13C NMR spectrum of 13d. 
 




Spectrum 2-42: 1H NMR spectrum of 13e. 
 




Spectrum 2-44: DEPT-135 NMR spectrum of 13e. 
 
 
